venlafaxine hydrochloride profile

Venlafaxine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) medication primarily used to treat major depressive disorder, generalized anxiety disorder, and social anxiety disorder. It was synthesized by the pharmaceutical company Wyeth in the late 1980s and approved by the Food and Drug Administration (FDA) in 1993. Venlafaxine acts by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters involved in mood regulation. Studies have shown that venlafaxine is effective in reducing depressive symptoms and anxiety, and it is often prescribed as a first-line treatment for these conditions. The compound is widely studied to understand its mechanisms of action, potential side effects, and optimal dosage for different patient populations. Venlafaxine has been found to be particularly effective in treating patients with severe depression or those who have not responded well to other antidepressant medications. However, it can cause adverse effects such as nausea, dizziness, and sexual dysfunction. Research continues to explore its effectiveness, long-term effects, and potential interactions with other medications.'

Venlafaxine Hydrochloride: A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	62923
CHEMBL ID	1201066
CHEBI ID	9944
SCHEMBL ID	41936
MeSH ID	M0136959

Synonym
AC-1696
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride
CHEBI:9944 ,
efexor
effexor lp
pw-4112
vandral
venlafaxine ea
pf-00345408
bvf-012
venlafaxine xr
efexor xl
effexor xl
dobupal
effexor
venlafaxine hydrochloride [usan]
wy-45,030
1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride
effexor xr
cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
venlafaxine hydrochloride
wy-45030
wy 45030
c17h27no2.hcl
1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol hcl
venlafaxine hcl
MLS001401454
smr000469154
effexor (tn)
D00821
venlafaxine hydrochloride (jan/usp)
99300-78-4
AKOS000280874
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol hydrochloride
venlafaxine (as hydrochloride)
CHEMBL1201066
(rs)-1-(2-dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride
nsc745751
nsc-745751
A845995
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-1-cyclohexanol hydrochloride
dtxcid6027397
NCGC00256703-01
cas-99300-78-4
tox21_302508
dtxsid8047397 ,
V0110
CCG-100979
venlafaxine hydrochloride [usan:usp]
7d7rx5a8mo ,
unii-7d7rx5a8mo
nsc 745751
FT-0642395
LP00449
S1441
AKOS016340594
venlafaxine hydrochloride [hsdb]
venlafaxine hydrochloride [who-dd]
venlafaxine hydrochloride [ep monograph]
venlafaxine hydrochloride [jan]
venlafaxine hydrochloride [mart.]
venlafaxine hydrochloride [orange book]
venlafaxine hydrochloride [mi]
venlafaxine hydrochloride [usp-rs]
venlafaxine hydrochloride [vandf]
(+/-)-1-(.alpha.-((dimethylamino)methyl)-p-methoxybenzyl)cyclohexanol hydrochloride
venlafaxine hydrochloride [usp monograph]
venlafaxine hydrochloride [ep impurity]
CCG-213270
HY-B0196A
venlafaxine (hydrochloride)
NC00229
SCHEMBL41936
KS-5049
NCGC00261134-01
tox21_500449
1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexanol -hcl
QYRYFNHXARDNFZ-UHFFFAOYSA-N
1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride
vexor
venlift
venlafaxine hydorchloride
venlafaxinehydrochloride
1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol hydrochloride
hydrochloride, venlafaxine
wy 45030 hydrochloride
(+/-)-1-(alpha-((dimethylamino)methyl)-p-methoxybenzyl)cyclohexanol hydrochloride
d,l-venlafaxine, hydrochloride
venlafaxine hydrochloride, united states pharmacopeia (usp) reference standard
venlafaxine hydrochloride, >=98% (hplc), powder
venlafaxine hydrochloride, pharmaceutical secondary standard; certified reference material
venlafaxine for system suitability, european pharmacopoeia (ep) reference standard
venlafaxine hydrochloride, european pharmacopoeia (ep) reference standard
venlafaxine hydrochloride 1.0 mg/ml in methanol (as free base)
venlafaxine hydro chloride
SW197609-3
BCP21401
HB1743
1-[2-(dimethylamino)-1-(4-methoxyph enyl)ethyl]cyclohexanol hydrochloride
Q27108525
AMY32694
venlafaxine hydrochloride 100 microg/ml in acetonitrile
dl-venlafaxine hydrochloride- bio-x
BV164514
cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride (1:1
EN300-124075
Z1557494602
venlafaxine hcler
venlafaxine hydrochloride (usp-rs)
venlafaxine hydrochloride (ep monograph)
venlafaxine hydrochloride (usan:usp)
venlafaxine hydrochloride (usp monograph)
effexorxr
venlafaxine hydrochloride (ep impurity)
venlafaxine hydrochloride, extended release
effexorxr extended-release
venlafaxine hydrochlorideer
venlafaxine hydrochloride (mart.)
1-((1rs)-2-dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexanol monohydrochloride
venlafaxine.hcl
venlafaxine.hcl, 1mg/ml in methanol

Excerpt	Reference	Relevance
"Venlafaxine hydrochloride (VEN) is an antidepressant drug widely used for the treatment of depression. "	( Solid-state evaluation and polymorphic quantification of venlafaxine hydrochloride raw materials using the Rietveld method. Bernardi, LS; Campos, CE; Cardoso, SG; Cuffini, SL; Ferreira, FF; Kuminek, G; Monti, GA; Oliveira, PR, 2013)	2.08
"Venlafaxine Hydrochloride (VH) is a highly soluble and highly permeable antidepressant compound. "	( Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form. Avachat, M; Kulkarni, S; Malewar, N; Pokharkar, V, 2015)	2.09
"Venlafaxine hydrochloride is a structurally novel antidepressant. "	( Preliminary data suggest that venlafaxine environmental concentrations could be toxic to plants. Catalá, M; Feito, R; Valcárcel, Y, 2013)	1.83
"Venlafaxine hydrochloride is a novel bicyclic antidepressant which inhibits the reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine. "	( A case report of venlafaxine toxicity. Burkhart, KK; Fantaskey, A, 1995)	1.73
"Venlafaxine hydrochloride is a structurally novel agent that has recently been approved in the US for the treatment of depression. "	( Venlafaxine: a structurally unique and novel antidepressant. Morton, WA; Sonne, SC; Verga, MA, 1995)	1.73
"Venlafaxine hydrochloride (Effexor) is a structurally novel antidepressant that inhibits reuptake of 5-hydroxytryptamine and noradrenaline, but unlike the older antidepressants, has few side-effects. "	( Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Denson, D; Hord, HA; Lang, E, 1996)	3.18

Excerpt	Reference	Relevance
"Venlafaxine has been shown in clinical trials to be safe and well tolerated in patients with major depression."	( Safety and tolerance profile of venlafaxine. Danjou, P; Hackett, D, 1995)	0.29
" During the study, the adverse events were generally mild to moderate and most subsided with continued treatment; the most frequent were nausea for venlafaxine and dry mouth for imipramine."	( Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Cohn, C; Crowder, J; Davidson, J; Dunner, D; Feighner, J; Kiev, A; Patrick, R; Shrivastava, RK, 1994)	0.29
" doses of venlafaxine are safe and effective in treating depression."	( Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Johnston, R; Mattes, J; Mendels, J; Riesenberg, R, 1993)	0.29
" Serious adverse events were rare among venlafaxine-treated patients."	( The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. Derivan, AT; Rudolph, RL, 1996)	0.58
" The rates for individual side effects with the serotonin selective reuptake inhibitors, nefazodone, and venlafaxine are presented and compared with the adverse event experience for mirtazapine."	( Safety and tolerability of the new antidepressants. Nelson, JC, 1997)	0.3
"The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration."	( Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Alpert, J; Fava, M; Mulroy, R; Nierenberg, AA; Rosenbaum, JF, 1997)	0.3
"During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference."	( Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Alpert, J; Fava, M; Mulroy, R; Nierenberg, AA; Rosenbaum, JF, 1997)	0.3
" In conclusion, our preliminary findings suggest that short-term, 6-week venlafaxine treatment may be a safe and effective antidepressant monotherapy for BP II major depression."	( Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. Amsterdam, J, 1998)	0.3
" The mechanism of action of antidepressants allows prediction of both adverse effects and therapeutic effects."	( Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Stahl, SM, 1998)	0.3
" The adverse events were not essentially different between treatment groups."	( Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson, JR; DuPont, RL; Haskins, JT; Hedges, D, 1999)	0.3
" Even though the small number of patients used is a significant limitation of this study, we found that combined venlafaxine and ECT appears to be safe when used in depression."	( Seizure activity and safety in combined treatment with venlafaxine and ECT: a pilot study. Arrufat, FJ; Baeza, I; Bernardo, M; Navarro, V; Salvà, J, 2000)	0.31
" They have a side effect profile that is different from the older drugs and are generally better tolerated."	( Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Sarko, J, 2000)	0.31
" This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.31
" A measure of side-effect intensity distinguished paroxetine from the other antidepressants on a measure of sexual dysfunction."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.31
"These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.31
" Treatment seems to be safe at venlafaxine doses <300 mg/day."	( Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression. Elizagarate, E; Gonzalez, N; Gonzalez-Pinto, A; Gutierrez, M; Mico, JA; Perez de Heredia, JL, 2002)	0.31
"Selective serotonin reuptake inhibitors (SSRIs) and venlafaxine have been regarded as less toxic in overdose than tricyclic antidepressants (TCAs)."	( Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Buckley, NA; Dawson, AH; Whyte, IM, 2003)	0.32
" Adverse events were monitored and recorded systematically during the trial."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.32
"Twelve subjects were discontinued due to serious adverse events (SAE), 5 were discontinued due to other significant side effects, and 2 withdrew consent."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.32
"In this frail elderly population, venlafaxine was less well tolerated and, possibly, less safe than sertraline without evidence for an increase in efficacy."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.32
" Selective serotonin and serotonin-noradrenaline re-uptake inhibitors have become more viable treatments for GAD than the traditionally used benzodiazepines due to greater efficacy and a more tolerable adverse event profile."	( The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? Gupta, S; Masand, PS, 2003)	0.32
" Adverse events were recorded at each visit."	( Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Dierkes, W; Huppertz-Helmhold, S; Sauer, H, 2003)	0.32
" Venlafaxine ER showed a more favorable safety profile than amitriptyline ER: adverse drug reactions were less frequent under venlafaxine ER than under amitriptyline ER."	( Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Dierkes, W; Huppertz-Helmhold, S; Sauer, H, 2003)	0.32
"2%) reported adverse events."	( [Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release]. Baca Baldomero, E; Cervera Enguix, S, )	0.13
"Venlafaxine extended release is a safe and effective drug that reduces depressive symptoms of Primary Health Care patients and improves their quality of life."	( [Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release]. Baca Baldomero, E; Cervera Enguix, S, )	0.13
"Mirtazapine and nefazadone appear safe in overdose and were associated with minimal features of neurological or cardiovascular toxicity."	( Comparative toxicity of citalopram and the newer antidepressants after overdose. Bateman, DN; Dhaun, N; Good, AM; Kelly, CA; Laing, WJ; Strachan, FE, 2004)	0.32
"This study attempted to determine if extended-release venlafaxine is safe for use in severely medically and surgically ill depressed patients."	( Safety and tolerability of extended-release venlafaxine in severe medical and surgical illness. Jindal, S; Schwartz, T; Virk, S; Wade, M, )	0.13
"Extended-release venlafaxine appears to be a safe and tolerable agent for the medical-surgical depressed inpatient."	( Safety and tolerability of extended-release venlafaxine in severe medical and surgical illness. Jindal, S; Schwartz, T; Virk, S; Wade, M, )	0.13
" Side effect burden, characterized as the mean number of side effects per postrandomization visit, correlated significantly with neurophysiologic changes in the antidepressant group but not the placebo group."	( Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Abrams, M; Cook, IA; DeBrota, DJ; Hunter, AM; Leuchter, AF; Morgan, ML; Potter, WZ; Siegman, B, 2005)	0.33
" Adverse events and patient satisfaction were also evaluated during these visits."	( The efficacy and safety of venlafaxine in the prophylaxis of migraine. Disci, R; Ertas, M; Kiziltan, E; Ozyalcin, SN; Talu, GK; Yucel, B, 2005)	0.33
"Venlafaxine was more effective than placebo and is safe and well tolerated as migraine prophylaxis."	( The efficacy and safety of venlafaxine in the prophylaxis of migraine. Disci, R; Ertas, M; Kiziltan, E; Ozyalcin, SN; Talu, GK; Yucel, B, 2005)	0.33
" Discontinuation rates due to associated adverse events were greatest in the venlafaxine treatment group: venlafaxine, 20."	( Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Kasper, S; Montgomery, SA; Pande, AC; Tobias, K; Zornberg, GL, 2006)	0.33
" Common adverse events were asthenia, anorexia, pain, and somnolence."	( Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Kunz, NR; Riddle, MA; Rynn, MA; Yeung, PP, 2007)	0.34
" Seven adverse events were recorded for four patients (6."	( Effectiveness and safety of venlafaxine extended release in elderly depressed patients. Carrasco, JL; García-Calvo, C; Ibor, JJ; Prieto, R, )	0.13
" As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen."	( Safety profile of treatment in diabetic peripheral neuropathic pain. Robinson-Papp, J; Simpson, DM, 2007)	0.34
" The efficacy of two treatments was assessed every 2 weeks during treatment, and at the end of study, using responses to IIEF, IELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects."	( Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. Safarinejad, MR, 2008)	0.35
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	0.35
" The most common treatment-emergent adverse events were nausea, dizziness, insomnia, constipation, fatigue, anxiety, and decreased appetite."	( Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Boyer, P; Brisard, C; Ganguly, R; Germain, JM; Lepola, U; Montgomery, S; Padmanabhan, SK; Tourian, KA, 2008)	0.35
"The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
", suicidal and non-suicidal self-injury adverse events were assessed by spontaneous report for the first 181 participants, and by systematic weekly assessment for the last 153 participants."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"2%), but not serious adverse events (8."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"Since predictors of suicidal adverse events also predict poor response to treatment, and many of these events occurred early in treatment, improving the speed of response to depression, by targeting of family conflict, suicidal ideation, and drug use may help to reduce their incidence."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
" Treatment-emergent adverse events, laboratory values, vital signs, and discontinuation symptoms were evaluated."	( An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Clayton, AH; Guico-Pabia, C; Kornstein, SG; Rosas, G; Tourian, KA, 2009)	0.35
"In the overall population (placebo: n=1,116; desvenlafaxine: n=1,834), adverse events resulted in discontinuations in 3% of placebo-treated patients and 12% of desvenlafaxine-treated patients; in the subset of fixed-dose studies, the rates were 4% with placebo and increased with desvenlafaxine dose (50 mg/day: 4%; 400 mg/day: 18%)."	( An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Clayton, AH; Guico-Pabia, C; Kornstein, SG; Rosas, G; Tourian, KA, 2009)	0.35
" The most common adverse event was transient nausea."	( An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Clayton, AH; Guico-Pabia, C; Kornstein, SG; Rosas, G; Tourian, KA, 2009)	0.35
" There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT."	( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009)	0.35
"To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects."	( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009)	0.35
"Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects."	( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009)	0.35
"Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo."	( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009)	0.35
"The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects."	( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009)	0.35
" Agomelatine is probably hepatotoxic; (8) In summary, agomelatine has unproven efficacy and poorly documented adverse effects."	( Agomelatine: new drug. Adverse effects and no proven efficacy. , 2009)	0.35
"An antidepressant's tolerability, generally captured as the frequency and severity of adverse events (AEs), is often as important as its efficacy in determining treatment success."	( Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP, 2011)	0.37
" The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea."	( Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. Alexander, R; Archer, G; Evoniuk, G; Graff, O; Krishnan, KR; Lavergne, A; Learned, S; Moate, R; Modell, JG; Ratti, E; Roychowdhury, S; Zamuner, S, 2012)	0.38
" Tolerability and safety were compared by an evaluation of reported adverse events."	( An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. Canny, LM; Coleman, KA; Meaney, JV; Palmer, TL; Radalj, LM; Xavier, VY, 2012)	0.38
" Adverse effects were also evaluated."	( Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Berk, M; Freeman, RD; Ghanizadeh, A, 2013)	0.39
" We chose the number of patients experiencing = 50% reduction in pain and number of patient withdrawals due to adverse events (AE) as primary outcomes for efficacy and safety, respectively."	( Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Bansal, D; Bhansali, A; Ghai, B; Gudala, K; Hota, D; Rudroju, N; Talakokkula, ST, )	0.13
"Gabapentin was found to be most efficacious and amitriptyline to be least safe among the treatments included in the study."	( Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Bansal, D; Bhansali, A; Ghai, B; Gudala, K; Hota, D; Rudroju, N; Talakokkula, ST, )	0.13
"The aim of this study was to assess whether the combination of low frequency repetitive transcranial magnetic stimulation (rTMS) and venlafaxine (150-225 mg/day) is effective and safe for treatment-resistant unipolar depression (TRD)."	( The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. Attal, J; Brault, C; Brunelin, J; Gay, A; Haffen, E; Jalenques, I; Januel, D; Poulet, E; Schott-Pethelaz, AM; Szekely, D; Trojak, B, )	0.13
" No neonatal adverse events emerged, so far, in the few studies concerning the safety of SNRIs during breastfeeding."	( The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Mandarelli, G; Martini, MG; Nardi, B; Vargas, M, 2015)	0.42
"Available data suggest that venlafaxine is relatively safe during pregnancy, in particular as far as major malformations are concerned, whereas considering the small number of studies published, no definitive conclusions can be drawn on its safety during breastfeeding."	( The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Mandarelli, G; Martini, MG; Nardi, B; Vargas, M, 2015)	0.42
" Furthermore, combination therapy provides less adverse effects."	( [Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit]. Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB, 2015)	0.42
" Treatment-related adverse events in the treatment period were 51."	( A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. Asami, Y; Higuchi, T; Imaeda, T; Itamura, R; Kamijima, K; Kuribayashi, K; Nakagome, K, 2016)	0.43
" Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference."	( The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Baldwin, DS; Chrones, L; Florea, I; Nielsen, R; Nomikos, GG; Palo, W; Reines, E, 2016)	0.43
" The association between a drug and a rare but potentially serious side effect in an individual patient can be difficult to determine with precision, and the decision to press ahead and try to work around the reaction, versus stopping the likely offender and finding a substitute, is a matter for seasoned clinical judgment."	( Commentary on 2 Cases of Rare but Serious Side Effects of Commonly Used Medications: Dilemmas in Clinical Decision-making. Kahn, DA, 2018)	0.48
" Moreover, co-exposure with microplastic might lead to more adverse effect against loach."	( Enantiospecific toxicity, distribution and bioaccumulation of chiral antidepressant venlafaxine and its metabolite in loach (Misgurnus anguillicaudatus) co-exposed to microplastic and the drugs. Duan, L; Ma, R; Qu, H; Wang, B; Yang, J; Yu, G, 2019)	0.51
"The time course of adverse events is an important factor for patient management."	( The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder. Cleary, S; Gallop, R; Rickels, K, )	0.13
" Adverse events were assessed at each treatment visit using a 21-item checklist."	( The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder. Cleary, S; Gallop, R; Rickels, K, )	0.13
" A highly significant race effect was found in that whites had a significantly higher adverse event rate than did nonwhites."	( The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder. Cleary, S; Gallop, R; Rickels, K, )	0.13
"Our findings provide information for clinicians on the course of adverse events over treatment, useful to prepare patients for treatment adherence."	( The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder. Cleary, S; Gallop, R; Rickels, K, )	0.13
" The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache."	( Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D, 2019)	0.51
" The most frequent adverse events (AEs) were dizziness and somnolence in the trazodone group, and nausea and headache in the venlafaxine group."	( A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Albert, U; Cattaneo, A; Comandini, A; Di Dato, G; Di Loreto, G; Fagiolini, A; Ferrando, L; Herman, E; Kasper, S; Muntean, C; Olivieri, L; Pálová, E; Salvatori, E; Tongiani, S, 2020)	0.56
" However, investigation of their toxic effects on aquatic animals, single or in mixture with other occurring psychoactive drugs, has been neglected."	( Norfluoxetine and venlafaxine in zebrafish larvae: Single and combined toxicity of two pharmaceutical products relevant for risk assessment. Cunha, V; Ferreira, M; Guimarães, L; Oliva-Teles, L; Rodrigues, P, 2020)	0.56
" Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures."	( Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021)	0.62
"5 mg/day) treatment during the first hospitalization did not cause any side effects, but treatment with mirtazapine (15 mg/day) and venlafaxine (150 mg/day) during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization."	( A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation. Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N, 2022)	0.72
" The results revealed the transformation pathways of these drugs under the UV disinfection process in wastewater treatment plants, especially the formation of toxic by-products during the disinfection process."	( Ultraviolet oxidative degradation of typical antidepressants: Pathway, product toxicity, and DFT theoretical calculation. Ji, Y; Lin, W; Ping, S; Ren, Y; Zhang, X; Zhao, B, 2022)	0.72
" Moreover, previous reviews have not systematically assessed the occurrence of adverse events."	( The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Gluud, C; Hengartner, MP; Horowitz, MA; Jakobsen, JC; Juul, S; Jørgensen, CK; Kirsch, I; Moncrieff, J; Munkholm, K; Siddiqui, F, 2023)	0.91
" The primary outcomes will be suicides or suicide attempts, serious adverse events, and non-serious adverse events."	( The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Gluud, C; Hengartner, MP; Horowitz, MA; Jakobsen, JC; Juul, S; Jørgensen, CK; Kirsch, I; Moncrieff, J; Munkholm, K; Siddiqui, F, 2023)	0.91
" As antidepressants are frequently used for postpartum depression (PPD) treatment, this study investigated the adverse effects of lactational exposure to venlafaxine (VENL, a selective SNRI) on mammary gland development and carcinogenesis in F1 female offspring."	( Safety of lactational exposure to venlafaxine on the rat mammary gland development and carcinogenesis in F1 female offspring. Altieri, MA; Arena, AC; Barbisan, LF; da Silva Moreira, S; da Silva, AS; Zapaterini, JR, 2023)	0.91

Excerpt	Reference	Relevance
" A randomized three-period crossover study was conducted to obtain pharmacokinetic and dose proportionality data on the drug and its active metabolite, O-desmethylvenlafaxine."	( Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. Chiang, ST; Jusko, WJ; Klamerus, KJ; Maloney, K; Rudolph, RL; Sisenwine, SF, 1992)	0.28
" Analysis of variance showed no significant differences between the two venlafaxine regimens for peak concentration (Cmax), area under the curve during 24 hours (AUC0-24), trough concentration, or fluctuation ratio for venlafaxine or O-desmethylvenlafaxine in plasma."	( The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Chiang, ST; Fruncillo, RJ; Parker, VD; Troy, SM, 1995)	0.29
"To assess possible pharmacokinetic and pharmacodynamic interactions between the antidepressant venlafaxine and diazepam, a randomized, two-period, crossover study was conducted in 18 men."	( Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. Chiang, ST; Klockowski, PM; Lucki, I; Parker, VD; Peirgies, AA; Troy, SM, 1995)	0.29
" Other species differences were seen, including an elimination half-life of venlafaxine that was longer in dog and rhesus monkey (2-4 h) than in rodent (around 1 h)."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" Thus, there were no clinically significant pharmacokinetic interactions between venlafaxine and lithium."	( Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. Boudino, FD; Chiang, ST; Hicks, DR; Parker, VD; Troy, SM, 1996)	0.29
"This single- and multiple-dose, nonrandomized, inpatient study was conducted to determine the effects of age and gender on the pharmacokinetic profiles of the antidepressant venlafaxine and its equally active metabolite, O-desmethylvenlafaxine."	( Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Chiang, ST; Derivan, AT; Klamerus, KJ; Parker, VD; Rudolph, RL, )	0.13
" The pharmacokinetic disposition of VEN was characterized using a "first-pass" model that incorporates a presystemic compartment (liver) to account for the first-pass metabolism of VEN to ODV."	( Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. Behar, L; DiGregorio, RV; Iyer, GR; Taft, DR, 1997)	0.3
" A standard, medium-fat breakfast eaten immediately before drug administration delayed the tmax of venlafaxine but did not affect Cmax or AUC."	( Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. Chiang, ST; Hicks, DR; Parker, VP; Pollack, GM; Troy, SM, 1997)	0.3
" Because many patients taking antidepressant therapy may self-medicate with ethanol, this study was undertaken to assess the possible pharmacokinetic and pharmacodynamic interactions between venlafaxine and ethanol."	( Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. Chiang, ST; Parker, VD; Troy, SM; Turner, MB; Unruh, M, 1997)	0.3
"To document a case of serotonin syndrome associated with venlafaxine and fluoxetine that did not involve a monoamine oxidase inhibitor, and to examine the multiple factors, including pharmacodynamic and pharmacokinetic interactions, that likely caused this adverse drug reaction (ADR)."	( Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998)	0.3
", an idiosyncratic reaction to venlafaxine), a pharmacokinetic interaction, a pharmacodynamic interaction, a combined pharmacokinetic-pharmacodynamic interaction, and the patient' s panic disorder."	( Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998)	0.3
"Potential pharmacokinetic effects of venlafaxine on alprazolam, a substrate of the cytochrome pigment 450 (CYP) isoenzyme CYP3A4, were investigated in 16 healthy volunteers."	( Effect of venlafaxine on the pharmacokinetics of alprazolam. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1998)	0.3
"The effect of steady-state venlafaxine administration on the single-dose pharmacokinetic profile of terfenadine, a cytochrome pigment (P450) isoenzyme CYP3A4 substrate, and its active acid metabolite (fexofenadine) was evaluated in an open-label, nonrandomized study."	( Effect of venlafaxine on the pharmacokinetics of terfenadine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1998)	0.3
" This open-label study evaluated the effect of steady-state venlafaxine on CYP1A2-dependent metabolism, as measured by the pharmacokinetic disposition of caffeine, and urinary caffeine metabolite ratios (CMRs)."	( Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
"An open-label study evaluated the effect of steady-state venlafaxine on the single-dose pharmacokinetic profile of risperidone, a CYP2D6 substrate; its active metabolite, 9-hydroxyrisperidone; and the total active moiety (risperidone plus 9-hydroxyrisperidone)."	( Effect of venlafaxine on the pharmacokinetics of risperidone. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
"The Cmax and AUC of venlafaxine were 184% and 484% higher in the group 1 subjects than in the group 3 subjects, and 101% and 203% higher in the group 1 than in the group 2, respectively."	( Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Azuma, J; Fukuda, T; Nishida, Y; Ohno, M; Takada, K; Yamamoto, I; Zhou, Q, 1999)	0.3
" Pharmacokinetic and pharmacodynamic changes in this population may predispose patients to experience an increased number of adverse events."	( Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, CL; Pollock, BG, 1999)	0.3
" Considerations relevant to drug product selection include: 1) pharmacokinetic issues such as half-life and time to steady-state, and protein binding; 2) pharmacodynamic drug-drug interactions; and 3) drug metabolism-related drug interactions."	( Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Dugan, D; Ereshefsky, L, 2000)	0.31
" The aim of the present study was to determine the acute pharmacodynamic effects of citalopram and venlafaxine, on cognitive and psychomotor performance."	( Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Nathan, PJ; Sali, A; Silberstein, RB; Sitaram, G; Stough, C, 2000)	0.31
" The present study assessed the distribution of VEN in different compartments, whether the VEN concentration in the compartments correlated, the effect of VEN on dialysate monoamine levels and on the spontaneous open-field behavior, and possible relations between the pharmacokinetic and pharmacodynamic parameters."	( Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings. Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hjorth, S; Kullingsjö, J; Lundmark, J; Wikell, C, 2001)	0.31
" The liver impairment may result in pharmacokinetic alterations of the antidepressant drug, which in turn may affect the already perturbed monoaminergic function."	( Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy. Apelqvist, G; Bengtsson, F; Hjorth, S; Kugelberg, FC; Wikell, C, )	0.13
" Based on the pharmacologic characteristics of venlafaxine and indinavir, we hypothesized that significant pharmacokinetic drug-drug interactions would not occur when these drugs where taken concurrently."	( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001)	0.31
" Potential pharmacokinetic advantages of these formulations include lower peak plasma drug concentrations and smaller fluctuations between peak and trough plasma drug concentrations, which might influence the tolerability of these medications."	( Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, CL, 2003)	0.32
" Ten CYP2D6 genotyped and depressive (F32x and F33x, ICD-10) patients participated in an open study on the pharmacokinetic and pharmacodynamic consequences of a carbamazepine augmentation in VEN non-responders."	( Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. Baumann, P; Brawand-Amey, M; Brocard, M; Ciusani, E; Eap, CB; Zullino, DF, 2004)	0.32
" A more rapid achievement by venlafaxine of remission and a high-quality pharmacokinetic and pharmacodynamic profile lead to patient compliance and facilitate both fewer relapses and recurrences."	( The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Barkin, RL; Barkin, S, )	0.13
" The method was successfully applied for the evaluation of pharmacokinetic profiles of venlafaxine capsule in 20 healthy volunteers."	( Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. Bing-Ren, X; Cai-Yun, W; Wei, Z, 2007)	0.34
" Blood samples were collected for pharmacokinetic analysis of ADTs."	( The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010)	0.36
" We used pupillography as a test system for the pharmacodynamic response to venlafaxine, since it had been shown to be useful for assessment of noradrenergic effects on the autonomous nervous system."	( Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. Jaehde, U; Jung, A; Kirch, W; Lindauer, A; Oertel, R; Siepmann, M; Siepmann, T; Ziemssen, T, 2008)	0.35
"The pharmacokinetic part of the model could be simultaneously fitted to both venlafaxine and O-desmethylvenlafaxine data, yielding precise parameter estimates that were similar to published data."	( Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. Jaehde, U; Jung, A; Kirch, W; Lindauer, A; Oertel, R; Siepmann, M; Siepmann, T; Ziemssen, T, 2008)	0.35
" Comparisons of AUC and Cmax between cytochrome P450 2D6 EMs and PMs were calculated using a Wilcoxon exact test."	( Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Ahmed, S; Burczynski, ME; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Preskorn, S; Silman, H, 2009)	0.35
" This reduced pharmacokinetic variability of desvenlafaxine may translate into better uniformity of response for patients receiving desvenlafaxine versus venlafaxine, but additional studies are required to test this hypothesis."	( Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Ahmed, S; Burczynski, ME; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Preskorn, S; Silman, H, 2009)	0.35
" The aim of the present pilot study was to compare the pharmacokinetic profiles of brand-name and generic formulations of citalopram and extended-release venlafaxine."	( Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. Batten, LA; Blier, P; Chenu, F; Hébert, C; Ladstaetter, E; Zernig, G, 2009)	0.35
" The method herein described was superior to previous methods in sensitivity and sample throughput and successfully applied to clinical pharmacokinetic study of venlafaxine sustained-release capsule in healthy male volunteers after oral administration."	( Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Li, F; Li, N; Qin, F; Qin, T; Zhang, Y, 2010)	0.36
" The pharmacokinetic parameters of VenHCl from the optimized three-layer tablet was compared to the marketed extended release capsule as a reference in healthy human subjects using a randomized crossover design."	( Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. Aboelwafa, AA; Basalious, EB, 2010)	0.59
"Genetically driven variations in the level of cytochrome P450 (CYP) 2D6 metabolic activity have been shown to significantly affect the pharmacokinetic behaviour of medications that are substrates of this enzyme."	( Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Focht, K; Jiang, Q; Kane, CP; Nichols, AI; Preskorn, SH, 2011)	0.37
" Blood samples for pharmacokinetic analyses were collected during the 120 hours following administration of each study drug."	( Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Focht, K; Jiang, Q; Kane, CP; Nichols, AI; Preskorn, SH, 2011)	0.37
"An HPLC-MS/MS method has been developed and validated for the determination of venlafaxine enantiomers in human plasma and applied to a pharmacokinetic study in healthy Chinese volunteers."	( Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers. Dai, YC; Deng, N; Liu, W; Liu, XR, 2011)	0.37
"To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" Formulation was optimized on the basis of clarity, pH, gelation temperature, mucoadhesive strength, gel strength, viscosity, drug content, diffusion through sheep nasal mucosa, histopathological evaluation of mucosa, and pharmacodynamic study in rats."	( Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation. Avachat, AM; Bhandwalkar, MJ, 2013)	0.66
" Mechanistic pharmacokinetic simulations suggested that the low metabolite ratio was the result of combined poor metabolizer (PM) status of cytochrome P450 (CYP) 2C19 and CYP2D6."	( A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Ahlner, J; Boel, LW; Brock, B; Jornil, J; Nielsen, TS; Rosendal, I; Zackrisson, AL, 2013)	0.39
"Among 80 enrolled subjects, 77 were included in pharmacokinetic and safety analyses."	( An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Corcoran, M; Ermer, J; Haffey, MB; Harlin, B; Lasseter, K; Martin, P; Purkayastha, J; Richards, C; Roesch, B, 2013)	0.39
" The impact of venlafaxine on ticagrelor pharmacokinetic parameters was also investigated."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
" Plasma concentrations of ticagrelor, venlafaxine, and their metabolites (AR-C124910XX and O-desmethylvenlafaxine [ODV], respectively) were quantified for pharmacokinetic analyses."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
" Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
"To evaluate the ability of two biomarkers in reflecting venlafaxine pharmacokinetic variations, and to further examine their relationship with venlafaxine treatment outcomes."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.42
"Two well-defined influencing factors: CYP2D6 genotypes and drug interactions were enriched into a three-period crossover study to produce venlafaxine pharmacokinetic variations: In each period, healthy CYP2D6 extensive metabolizers (EM group; n = 12) and CYP2D610/10 intermediate metabolizers (IM group; n = 12) were pretreated with clarithromycin (CYP3A4 inhibitor), or nothing (control), or clarithromycin + paroxetine (CYP3A4 + CYP2D6 inhibitors), before administration of a single-dose of 75 mg venlafaxine."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.42
"Our results indicated that an intake of apigenin could increase VEN plasma levels and some of its pharmacokinetic parameters (AUC, Tmax)."	( Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro. Gu, EM; Hu, GX; Hu, XX; Liang, BQ; Lin, D; Zhan, YY; Zheng, ZQ, 2015)	0.42
" In this article, we report the evidence that contributed to the implementation of pharmacokinetic pharmacogenetic guidelines for antidepressants primarily metabolized by CYP2D6 and CYP2C19."	( Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR, 2016)	0.43
" A physiologically based pharmacokinetic absorption model was established and verified to simulate the pharmacokinetic profiles after a single-dose oral administration of ER venlafaxine HCl tablets based on an osmotic pump or openable matrix design."	( Physiologically Based Pharmacokinetic Modeling for Substitutability Analysis of Venlafaxine Hydrochloride Extended-Release Formulations Using Different Release Mechanisms: Osmotic Pump Versus Openable Matrix. Lin, HP; Sun, D; Wen, H; Zhang, X, 2016)	0.66
"To uncover pharmacokinetic interactions between venlafaxine and doxepin or mirtazapine in a naturalistic sample."	( Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
" Validated method was successfully applied to a pharmacokinetic study of VEN orally administered to rats."	( Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. Bakhtiar, R; Black, M; Cookson, C; Fiorella, A; Gorman, SH; Gu, G; Li, Y, 2018)	0.48
"9 kg/m²), and high-BMI (≥30 kg/m²) groups, higher values of some pharmacokinetic variables in the lower BMI group did not remain significant after controlling for sex."	( Sex and body weight are major determinants of venlafaxine pharmacokinetics. Correll, CU; Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
" Although of special clinical relevance, data on pharmacokinetic interactions between AMLO, RAMI, and venlafaxine (VEN) are lacking."	( How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. Augustin, M; Gründer, G; Haen, E; Paulzen, M; Schoretsanitis, G, 2018)	0.48
" Significant associations were found among 3 CYP2D6 phenotypes (NM, IM, and PM) and most pharmacokinetic parameters of venlafaxine."	( The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis. Cai, WK; He, F; He, GH; Lin, XQ; Sun, M; Wang, P; Xu, GL; Yang, M; Zhou, MD, 2019)	0.51
"The purpose of this study was to identify specific pharmacokinetic (PK) and pharmacodynamics (PD) factors that affect the likelihood of treatment remission with a serotonin norepinephrine reuptake inhibitor (SNRI) in depressed patients whose initial selective serotonin reuptake inhibitor (SSRI) failed."	( Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Ahmed, AT; Biernacka, JM; Bobo, WV; Frye, MA; Hall-Flavin, DK; Jenkins, G; Kung, S; Rush, AJ; Shinozaki, G; Veldic, M; Wang, L; Weinshilboum, RM, 2019)	0.51
" We also investigated potential pharmacokinetic correlates of the four UKU categories by comparing patients complaining ADRs with those who did not."	( Pharmacokinetic correlates of venlafaxine: associated adverse reactions. Endres, K; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Ridders, F; Schoretsanitis, G; Veselinovic, T, 2019)	0.51
" As such, kratom may precipitate pharmacokinetic drug interactions when co-consumed with certain medications."	( A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone. Brogdon, HD; Burns, AG; Cox, EJ; McPhee, MM; Paine, MF, )	0.13
"Preclinical pharmacokinetic (PK) studies in animal models during the formulation development phase give preliminary evidence and near clear picture of the PK behavior of drug and/or its dosage forms before clinical studies on humans and help in the tailoring of the dosage form according to the expected and requisite clinical behavior."	( Multiple-reaction monitoring (MRM) LC-MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits. Ahmad, S; Fazli, AA; Khan, NA; Khuroo, A; Kumar, V; Panigrahy, BK; Raza, SN; Wani, TU; Zarger, BA, 2022)	0.72

Excerpt	Reference	Relevance
"Selection of an antidepressant is influenced by many factors, including the patient's current drug regimen and the drug's potential for drug-drug interactions."	( Drug-drug interactions involving antidepressants: focus on venlafaxine. Ereshefsky, L, 1996)	0.29
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."	( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Richelson, E, 1997)	0.3
" Considerations relevant to drug product selection include: 1) pharmacokinetic issues such as half-life and time to steady-state, and protein binding; 2) pharmacodynamic drug-drug interactions; and 3) drug metabolism-related drug interactions."	( Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Dugan, D; Ereshefsky, L, 2000)	0.31
" Complications in treating depressed HIV-infected individuals include the use of multiple medications, additive side effects, and potentially significant drug-drug interactions."	( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001)	0.31
" Satisfactory release profiles were obtained when VEN pellets were prepared by 4% EC subcoating combined with 4% Eudragit(®) NE30D outercoating and 8% hot-melt subcoating combined with 6% Eudragit(®) NE30D outercoating, respectively."	( Comparative study of the stability of venlafaxine hydrochloride sustained-release pellets prepared by double-polymer coatings and hot-melt subcoating combined with Eudragit(®) NE30D outercoating. Guan, T; Li, G; Tang, X; Wang, J, 2011)	0.64
" In conclusion, the high suicide potential of VEN in combination with the high prevalence of drugs causing adverse interactions could be the reason for the observed high FTI."	( Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Launiainen, T; Ojanperä, I; Rasanen, I; Vuori, E, 2011)	0.37
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" Bearing in mind that VEN has exhibited large variability in antidepressant response, besides the individual genetic background, several other factors may contribute to those variable clinical outcomes, such as the occurrence of significant drug-drug interactions."	( Clinical drug-drug interactions: focus on venlafaxine. Alves, G; Falcão, A; LLerena, A; Magalhães, P, 2015)	0.42
" The technique has potential to identify drug-drug interaction involving VX and O-DVX enantiomers while administering indinivar therapy."	( Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. Eap, CB; Jann, M; Liu, Y; Shamsi, SA; Vandenberg, C, 2015)	0.42
"The study was a randomised pragmatic trial comparing venlafaxine and sertraline in combination with psychotherapy and social counselling."	( Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study. Bech, P; Carlsson, J; Elklit, A; Mortensen, EL; Sonne, C, 2016)	0.43
"Elderly patients with major depressive disorder, as defined by DSM-IV, received open-label high-dose, right unilateral ultrabrief pulse ECT, combined with venlafaxine, as part of participating in phase 1 of the National Institute of Mental Health-supported study Prolonging Remission in Depressed Elderly (PRIDE)."	( Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. Bailine, SH; Dooley, M; Greenberg, RM; Husain, MM; Kellner, CH; Knapp, RG; Lisanby, SH; McCall, WV; McClintock, SM; McCloud, L; Mueller, M; Petrides, G; Prudic, J; Riley, MA; Rosenquist, PB; Rudorfer, MV; Weiner, RD; Young, RC, )	0.13
"We found that ECT, combined with venlafaxine, has a modest anti-insomnia effect that is linked to its antidepressant effect."	( Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. Bailine, SH; Dooley, M; Greenberg, RM; Husain, MM; Kellner, CH; Knapp, RG; Lisanby, SH; McCall, WV; McClintock, SM; McCloud, L; Mueller, M; Petrides, G; Prudic, J; Riley, MA; Rosenquist, PB; Rudorfer, MV; Weiner, RD; Young, RC, )	0.13

Excerpt	Reference	Relevance
"The comparative bioavailability of the novel antidepressant venlafaxine and its pharmacologically active metabolite O-desmethylvenlafaxine was assessed when venlafaxine was given orally twice daily (75 mg bid) or 3 times daily (50 mg tid)."	( The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Chiang, ST; Fruncillo, RJ; Parker, VD; Troy, SM, 1995)	0.29
" Absolute bioavailability was low in rat and rhesus monkey (12."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" The pharmacokinetics and relative bioavailability of venlafaxine were evaluated in healthy volunteers after oral administration."	( Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. Chiang, ST; Hicks, DR; Parker, VP; Pollack, GM; Troy, SM, 1997)	0.3
" The absolute bioavailability of the conventional (CF) and extended-release (XR) formulations and their effects on electroencephalograms (EEG) and on a visual analog scale (VAS) for nausea were assessed in a randomized, double-blind, four-way crossover, placebo-controlled study of 16 healthy young men who were given either a single oral dose of 50 mg of CF venlafaxine, 75 mg of XR venlafaxine, or an intravenous dose of 10 mg of venlafaxine, or a placebo at 1-week intervals."	( Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. Allain, H; Burke, J; Danjou, P; Gandon, JM; Le Coz, F; Patat, A; Trocherie, S; Troy, S, 1998)	0.3
" Its function is to limit the bioavailability of orally administered compounds."	( Venlafaxine induces P-glycoprotein in human Caco-2 cells. Ehret, MJ; Levin, GM; Narasimhan, M; Rathinavelu, A, 2007)	0.34
" Relative bioavailability was 103."	( Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. Bing-Ren, X; Cai-Yun, W; Wei, Z, 2007)	0.34
" The aim of this study was to determine whether in major depression changes in the activity patterns of local modulators of glucocorticoid action might contribute to an increase in cortisol bioavailability and if they change during antidepressant treatment and clinical response."	( Cortisol metabolism in depressed patients and healthy controls. Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009)	0.35
" These changes suggest an increase in cortisol bioavailability within tissues."	( Cortisol metabolism in depressed patients and healthy controls. Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009)	0.35
" Further, the bioavailability study using the New Zealand rabbits was carried out."	( In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. Gattani, S; Nerkar, PP, 2011)	0.37
" The bioavailability of F5 by buccal route was 54."	( Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: in vivo, in vitro evaluation. Gattani, SG; Nerkar, PP, 2012)	0.38
" The relative bioavailability for Formulation 1 and Formulation 2 was evaluated in six healthy beagle dogs after oral administration in a fast state using sustained-release capsules (Effexor XR) as a reference."	( Preparation and in vitro/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets. He, Z; Liu, Y; Sun, J; Sun, M; Sun, Y; Zhao, N, 2012)	0.62
" However, few studies have assessed the bioavailability of pharmaceuticals to fish in natural waters."	( Bioavailability of pharmaceuticals in waters close to wastewater treatment plants: use of fish bile for exposure assessment. Brozinski, JM; Kronberg, L; Lahti, M; Oikari, A; Segner, H, 2012)	0.38
" Functional polymorphisms of ABCB1 may influence central nervous system bioavailability of antidepressants subject to efflux."	( ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Berk, M; Bousman, CA; Byron, K; Ng, CH; Singh, AB, 2012)	0.38
"In order to improve the bioavailability of the antidepressant drug, venlafaxine hydrochloride, in situ mucoadhesive thermoreversible gel, was formulated using Lutrol F127 (18%) as a thermo gelling polymer."	( Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation. Avachat, AM; Bhandwalkar, MJ, 2013)	0.9
" Buccal administration of venlafaxine will avoid first pass metabolism, which will increase the bioavailability of the drug."	( Oromucosal delivery of venlafaxine by linseed mucilage based gel: in vitro and in vivo evaluation in rabbits. Gattani, SG; Nerkar, PP, 2013)	0.39
" However, in the periphery, venlafaxine treatment significantly reduced the topotecan oral bioavailability by nearly 40%, whereas the impact of desvenlafaxine on topotecan plasma levels was more modest (23%)."	( Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. Bachmeier, C; Beaulieu-Abdelahad, D; Levin, GM; Mullan, M; Reed, J, 2013)	0.39
" The antidepressant venlafaxine hydrochloride (Vx), a highly soluble drug undergoing first pass effect, low bioavailability and short half-life was selected as a challenging payload."	( Mini-tablets versus pellets as promising multiparticulate modified release delivery systems for highly soluble drugs. Abdallah, OY; Gaber, DM; Nafee, N, 2015)	0.74
" If their bioavailability is increased, this communication and the state of homeostasis may be disrupted."	( NMR-based metabonomic analysis of normal rat urine and faeces in response to (±)-venlafaxine treatment. García-Pérez, I; Meléndez-Camargo, ME; Serrano-Contreras, JI; Zepeda-Vallejo, LG, 2016)	0.43
" Pharmacokinetic parameters such as oral clearance, oral volume of distribution of the central compartment, time to reach maximum plasma concentration, absorption rate constant, and half-life in humans were predicted from animals using allometric scaling."	( Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach. Mahmood, I, 2016)	0.43
"5%, w/w) exhibited an elevated bioavailability compared to the commercial product, Effexor® XR."	( Engineering hot-melt extruded solid dispersion for controlled release of hydrophilic drugs. Fan, A; Meng, X; Tang, Y; Wang, G; Wang, Z; Zhang, S; Zhao, Y, 2017)	0.46
" 1-H-benzotriazole, carbamazepine, citalopram, lamotrigine, sucralose, tramadol, and venlafaxine (>80 % frequency of appearance in effluents) were assessed with respect to their bioavailability in soil as part of different scenarios of irrigation with reclaimed water following a qualitative approach."	( Multiclass target analysis of contaminants of emerging concern including transformation products, soil bioavailability assessment and retrospective screening as tools to evaluate risks associated with reclaimed water reuse. Beretsou, VG; Fatta-Kassinos, D; Lundy, L; Manoli, K; Michael, C; Nika, MC; Revitt, DM; Sui, Q; Thomaidis, NS, 2022)	0.72
"Short half-life and low bioavailability of Venlafaxine hydrochloride (VF), an antidepressant drug, necessitates the frequent administration of VF tablets in a day in order to maintain adequate drug concentration in blood plasma."	( Pluronic F-68 Montmorillonite As A Drug Delivery Vehicle For Extended Release Of Venlafaxine Hydrochloride. Datta, M; Jain, S, 2023)	1.4

Excerpt	Relevance	Reference
" In addition, venlafaxine has shown a dose-response relationship for efficacy, offering the possibility of a wide dose range, which may be suitably employed in different clinical situations."	( Clinical utility of venlafaxine in comparison with other antidepressants. Lecrubier, Y, 1995)	0.29
" A positive dose-response effect has been demonstrated with doses of up to 375 mg/day, with a minimum effective dose of 75 mg/day."	( Pharmacologic profile and efficacy of venlafaxine. Mendlewicz, J, 1995)	0.29
" Basic pharmacokinetic data and clinical trials are reviewed, as well as adverse reactions, drug interactions, dosing guidelines, and therapeutic considerations."	( Venlafaxine: a structurally unique and novel antidepressant. Morton, WA; Sonne, SC; Verga, MA, 1995)	0.29
" The usual daily dosage ranges from 75 to 225 mg/d in 2 to 3 divided doses, with a maximum daily dosage of 375 mg/d."	( Venlafaxine: a structurally unique and novel antidepressant. Morton, WA; Sonne, SC; Verga, MA, 1995)	0.29
" The dosage is 75-375 mg/day administered in two or three divided doses."	( Venlafaxine: a heterocyclic antidepressant. Ellingrod, VL; Perry, PJ, 1994)	0.29
" However, there are important differences among the newer antidepressants in terms of effects of P450 enzymes, dose-response curves for antidepressant response and adverse effects, and dosing schedules."	( Antidepressant drug selection: criteria and options. Preskorn, SH, 1994)	0.29
" In conclusion, the disposition of venlafaxine and O-desmethylvenlafaxine is markedly altered in renal disease; therefore dosage adjustment is warranted for patients with creatinine clearance values below 30 ml/min."	( The effect of renal disease on the disposition of venlafaxine. Blum, RA; Chiang, ST; Parker, VD; Schultz, RW; Troy, SM, 1994)	0.29
" Exposure of venlafaxine decreased with repeated dosing in mouse and rat, but was unchanged in dog."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" Dosage was flexible and administered on a three-times-a-day schedule, with a mean maximum daily dose of 182 mg for venlafaxine and 176 mg for imipramine."	( Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Feighner, J; Mandos, LA; Rickels, K; Schweizer, E, 1994)	0.29
" The efficacy and dose-response of venlafaxine, a novel serotonin and norepinephrine reuptake inhibitor, was evaluated in two placebo-controlled studies."	( Dose-response relationship with venlafaxine. Kelsey, JE, 1996)	0.29
" If the response was inadequate after two weeks of treatment, the dosage of venlafaxine could be increased to 75 mg twice daily."	( A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Dierick, M; Martin, A; Ravizza, L; Realini, R, 1996)	0.29
" We conclude that venlafaxine dosage adjustments for age or gender are not necessary based on pharmacokinetics."	( Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Chiang, ST; Derivan, AT; Klamerus, KJ; Parker, VD; Rudolph, RL, )	0.13
" Low dosage and short length of treatment may account for the lack of efficacy."	( Venlafaxine in the treatment of children and adolescents with major depression. Mandoki, MW; Parker, JL; Sumner, GS; Tapia, MA; Tapia, MR, 1997)	0.3
"6 years) with attention-deficit/hyperactivity disorder (ADHD) in order to estimate the appropriate dosage range and to determine the extent of side effects."	( An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Luh, J; Olvera, RL; Pliszka, SR; Tatum, R, 1996)	0.29
" Venlafaxine dosage needs to be lowered in the elderly with renal impairment."	( Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Goldberg, RJ, 1997)	0.3
"Venlafaxine (VEN), a drug used in the treatment of depression, undergoes significant first-pass metabolism after oral dosing to O-desmethylvenlafaxine (ODV), a metabolite with comparable therapeutic activity to that of parent drug."	( Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. Behar, L; DiGregorio, RV; Iyer, GR; Taft, DR, 1997)	0.3
" If the response was inadequate after 2 weeks of treatment, the dosage of venlafaxine XR or IR could be increased to 150 mg daily."	( Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Cunningham, LA, 1997)	0.3
" The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day)."	( The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. Entsuah, R; Khan, A; Leventer, SM; Rudolph, RL; Upton, GV, 1998)	0.3
"Each dosage of venlafaxine was associated with statistically significant improvement as compared with placebo, based on the intent-to-treat sample."	( A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Derivan, AT; Entsuah, R; Fabre, LF; Feighner, JP; Rickels, K; Rudolph, RL, 1998)	0.55
"Venlafaxine is currently marketed for treatment of depressive disorders as a conventional tablet formulation with a twice or three times daily dosage regimen."	( Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. Allain, H; Burke, J; Danjou, P; Gandon, JM; Le Coz, F; Patat, A; Trocherie, S; Troy, S, 1998)	0.3
" Despite a higher mean daily venlafaxine dosage for patients in the young group, no significant changes in systolic blood pressure were noted in either group."	( Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Brilmyer, M; Kant, R; Zeiler, D; Zimmer, B, 1997)	0.3
"Psychotropic drug dosing regimens are often based on the pharmacokinetic elimination half-life of the compound."	( Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. Amchin, J; Amsterdam, JD; Hooper, MB, 1998)	0.3
" We observed a significant reduction in mean weekly HAM-D and MADRS scores at weeks 1 through 6 for both dosing groups (p < ."	( Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. Amchin, J; Amsterdam, JD; Hooper, MB, 1998)	0.3
" Moreover, the present results suggest that the short elimination half-life of immediate-release venlafaxine should not be the sole determinant for multiple daily dosing and that antidepressant activity may be more profoundly influenced by a drug's pharmacodynamic half-life than by its pharmacokinetic half-life."	( Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. Amchin, J; Amsterdam, JD; Hooper, MB, 1998)	0.3
" On day 15, if clinically indicated to improve patient response, the dosage could be increased at the investigator's discretion to venlafaxine 75 mg twice daily or fluoxetine 40 mg once daily."	( A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Basquedano, G; Benassinni, O; Diaz-Martinez, A; Gonzalez, S; Martinez, RA; Ontiveros, A; Salin, R, )	0.13
" Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptable side effects and risks, other classes of medication have been studied as possible treatment alternatives."	( Psychopharmacology of ADHD: children and adolescents. Dogin, JW; Findling, RL, 1998)	0.3
" After a 1-week placebo lead-in, patients were randomly assigned to receive double-blind treatment with once- versus twice-daily venlafaxine dosing starting at 37."	( Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. Amsterdam, J, 1998)	0.3
" Blood samples were drawn before terfenadine dosing and at various intervals for 48 hours after dosing to measure plasma concentrations of terfenadine and its acid metabolite."	( Effect of venlafaxine on the pharmacokinetics of terfenadine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1998)	0.3
" Samples were collected before and for 24 hours after caffeine dosing for the determination of caffeine in plasma and 1,7-dimethylxanthine, 3,7-dimethylxanthine, 1,7-dimethyluric acid (17U), 1-methylxanthine (1X) and 1-methyluric acid (1U), and 5-acetylamino-6-amino-3-methyluracil (AAMU) in urine."	( Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
" Thirty healthy subjects received a 1 mg oral dose of risperidone before and after venlafaxine dosing to steady state."	( Effect of venlafaxine on the pharmacokinetics of risperidone. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
" In each session, dose-response curves to both locally infused noradrenaline acid tartrate (0."	( Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 1999)	0.3
" Recommended initial doses are lower for the elderly for all antidepressants, although optimal doses may not differ from those for younger patients once dosing is individualized."	( Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, CL; Pollock, BG, 1999)	0.3
" Blood and urine samples were collected under steady-state conditions over one dosing interval (12 h)."	( Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Hamelin, BA; LeBlanc, J; Lessard, E; O'Hara, G; Turgeon, J; Yessine, MA, 1999)	0.3
"To compare the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in outpatients with GAD without associated MDD."	( Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Aguiar, L; Gelenberg, AJ; Haskins, JT; Lydiard, RB; Rudolph, RL; Salinas, E, 2000)	0.31
" Its short half-life and time to steady-state, when coupled with the extended release characteristics of the preferred dosage formulation allow for once daily dosing and rapid attainment of therapeutic effects."	( Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Dugan, D; Ereshefsky, L, 2000)	0.31
" Pharmacological features of venlafaxine, which may benefit the patient with severe depression, include the possibility of a rapid onset of action and a dose-response curve."	( Efficacy of venlafaxine in the treatment of severe depression. Kienke, AS; Rosenbaum, JF, 2000)	0.31
" Dosing may have to be adjusted for patients with renal failure, but typically not for those with liver disease or other medical conditions."	( Efficacy of venlafaxine in geriatric depression. Evans, DL; Staab, JP, 2000)	0.31
" Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode."	( Seizures associated with therapeutic doses of venlafaxine and trimipramine. Drewe, J; Eggenberger, C; Klink, MH; Schlienger, RG, 2000)	0.31
" Such findings have enormous potential ramifications for practicing physicians in terms of venlafaxine's superior remission rate, lower likelihood of relapse, loss of fewer patients to adverse events or lack of efficacy, and flexibility in dosing that enables titration to achieve an optimal response."	( The pharmacoeconomics of venlafaxine in depression. Morrow, TJ, 2001)	0.31
" Further studies are needed to evaluate the potential of intermittent (luteal phase) dosing for this cyclic disorder and the efficacy of long-term maintenance treatment with venlafaxine."	( Venlafaxine in the treatment of premenstrual dysphoric disorder. Freeman, EW; Kunz, NR; McPherson, M; Rickels, K; Upton, GV; Yonkers, KA, 2001)	0.31
"25-5 mg/kg) did not affect the cocaine dose-response curve or its ED50 values."	( Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats? Filip, M; Papla, I, )	0.13
"A rapid, selective and stability indicating high performance liquid chromatographic method was developed and validated for the estimation of venlafaxine in pharmaceutical dosage forms."	( Stability indicating LC method for the estimation of venlafaxine in pharmaceutical formulations. Makhija, SN; Vavia, PR, 2002)	0.31
" The symptoms resolved when the dosage was kept constant and did not recur when the dosage was reduced more gradually."	( [Delirium during withdrawal of venlafaxine]. Koerselman, GF; van Noorden, MS; Vergouwen, AC, 2002)	0.31
" Methodological limitations included variability in definitions of treatment-resistant depression and response to treatment, dosing of medications, and reporting of adverse events."	( Combining antidepressants for treatment-resistant depression: a review. Cohen, NL; Kennedy, SH; Lam, RW; Wan, DD, 2002)	0.31
" Over the next 9 days, venlafaxine was administered at a dosage of 50 mg every 8 hours following a brief titration."	( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001)	0.31
"Patients with a DSM-IV diagnosis of OCD and a Yale-Brown Obsessive Compulsive Scale (YBOCS) score >/= 16 were randomly assigned to receive venlafaxine, 225 to 350 mg/day (26 patients), or clomipramine, 150 to 225 mg/day (47 patients), for 12 weeks, with dosage adjustments according to tolerability and response to treatment."	( Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Aguglia, E; Albert, U; Bogetto, F; Maina, G, 2002)	0.31
" A dose-response relationship was apparent, with the lowest rate of withdrawal seen at the highest venlafaxine XR dose."	( Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. Hackett, D; Haudiquet, V; Mahé, V; Montgomery, SA, 2002)	0.31
" Blood and urine samples were collected under steady-state conditions over one dosing interval (12 h)."	( Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Baumann, P; Brawand-Amey, M; Eap, CB; Lessard, E; O'Hara, G; Turgeon, J; Yessine, MA, 2003)	0.32
"This series of patients was gathered to assess the use of last and slow titration dosage of venlafaxine in in-patients with major depression and to evaluate the action onset."	( [Venlafaxine titration dosage in depressive in-patients. A series of cases]. Alberni, J; Bernardo, M; Buisán, E; Durán, A; Gascón, J; Prieto, R; Soler-Insa, PA, )	0.13
" For both patients symptoms occurred with lowering of the dosage and persisted for 5 days after complete discontinuation of the drug."	( Shock-like sensations during venlafaxine withdrawal. Beddingfield, JJ; Mack, JE; Reeves, RR, 2003)	0.32
" Thirty women with PMDD were enrolled and treated with a flexible dosage of venlafaxine for two menstrual cycles."	( Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Hsiao, MC; Liu, CY, 2003)	0.32
" This double action is dosage dependent, with the relatively weaker inhibition of norepinephrine becoming clinically relevant only at higher dosages."	( Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Dierkes, W; Linden, M; Ludewig, K; Munz, T, 2003)	0.32
"Data from a drug utilization observation (DUO) study, including 6706 patients, are used to investigate which patient and setting variables predict dosage of venlafaxine as prescribed by psychiatrists in inpatient and outpatient settings."	( Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Dierkes, W; Linden, M; Ludewig, K; Munz, T, 2003)	0.32
"Treatment setting is the most important factor in predicting high (> 75 mg/day) or low (up to 75 mg/day) dosage of venlafaxine, with inpatients receiving higher dosages."	( Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Dierkes, W; Linden, M; Ludewig, K; Munz, T, 2003)	0.32
"Venlafaxine at a dosage of 75 mg/day is sufficient for the majority of cases."	( Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Dierkes, W; Linden, M; Ludewig, K; Munz, T, 2003)	0.32
"Considering its modest sample size, naturalistic design and limited observation period, the present study provided preliminary indication that earlier clinical response may occur with higher V+ODV plasma level, extending previous dose-response studies."	( Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Balant, LP; Balant-Gorgia, AE; Bertschy, G; Gex-Fabry, M; Rudaz, S; Veuthey, JL, 2004)	0.32
" The longer apparent elimination half-life of the drug after single XR doses suggests that it is suitable for once daily dosing compared with the twice daily dosing regimen required by the IR formulation."	( The treatment of depression with different formulations of venlafaxine: a comparative analysis. Burrows, GD; Norman, TR; Olver, JS, 2004)	0.32
"5 mg/d, are reasonable initial dosages, and if symptoms do not improve within a week or two, the dosage can be doubled."	( Management of hot flashes in breast cancer survivors and men with prostate cancer. Stearns, V, 2004)	0.32
" Seventy outpatients fulfilling DSM-IV criteria for major depressive disorder were recruited into two demographically matched groups according to their daily dosage of venlafaxine: high dose n = 35 (> or = 375 mg/day, range 375-600 mg, average 437 mg/day) or standard dose n = 35 (< 375 mg/day, range 75-300 mg, average 195 mg/day."	( Tolerability of high-dose venlafaxine in depressed patients. Ferrier, N; Harrison, CL; Young, AH, 2004)	0.32
"The objective of this study was to examine the efficacy and tolerability of intermittent dosing of venlafaxine for the treatment of premenstrual dysphoric disorder."	( Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. Brandes, M; Cassano, P; Cohen, LS; Leblanc, GA; Lyster, A; Soares, CN, 2004)	0.32
"Patients received fixed dosing schedule (up to 300 mg/day) of venlafaxine (Effexor XR) for 8 weeks."	( An open trial of venlafaxine for the treatment of late-life atypical depression. Devanand, D; Fitzsimmons, L; Miyazaki, M; Roose, SP; Sackeim, H; Seidman, S; Turret, N, 2004)	0.32
" The utility of the neuroendocrine response to serotonergic (ipsapirone) and noradrenergic (clonidine) probes as predictors of venlafaxine dosage required for effective treatment was also explored."	( Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes. Goodman, M; Grossman, R; Mitropoulou, V; New, A; Reynolds, D; Schmeidler, J; Siever, LJ; Silverman, J, 2004)	0.32
" The study is designated as semi-naturalistic due to the fact that, although the venlafaxine treatment regimen was strictly defined, the timing of the trazodone introduction and the dosage were determined by the clinicians."	( Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Aït-Ameur, A; Bertschy, G; Ferrero, F; Muscionico, M; Osiek, C; Ragama-Pardos, E; Roth, L, 2005)	0.33
" In vivo studies demonstrated an intense but similar distribution pattern of phospho-p90Rsk staining after chronic venlafaxine dosing of rats compared to naives and no region-specific drug effect was observed in vivo."	( Effects of venlafaxine on p90Rsk activity in rat C6-gliomas and brain. Khawaja, XZ; Liang, JJ; Storm, S, 2004)	0.32
" The venlafaxine dosage was decreased to 150 mg/day, and symptoms gradually abated over 36 hours."	( Serotonin toxicity associated with concomitant use of linezolid. Bergeron, L; Boulé, M; Perreault, S, 2005)	0.33
"Clinicians should pay special attention to patients treated with serotonergic drugs, especially those receiving dosages in the higher end of the normal range who are prescribed linezolid, and consider tapering or reducing the dosage of serotonergic drugs for the duration of antibiotic therapy."	( Serotonin toxicity associated with concomitant use of linezolid. Bergeron, L; Boulé, M; Perreault, S, 2005)	0.33
" The onset of her symptoms correlated with a dosage increase of venlafaxine."	( Venlafaxine-associated interstitial pneumonitis. Gillam, DM; Nelson, JE; Roberts, BT; Turner, RC, 2005)	0.33
" Serious withdrawal symptoms may occur within hours of cessation or reduction of the usual dosage and may affect motor and coordination skills to such a degree that patients should be explicitly urged either to adhere to a strict medication routine or not to drive a car."	( Venlafaxine and serious withdrawal symptoms: warning to drivers. Campagne, DM, 2005)	0.33
" Both treatments were administered in a rapidly escalating dosing regimen."	( Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. Baker, RA; Benkert, O; Heinrich, C; Heukels, A; Kohnen, R; Philipp, M; Schutte, AJ; Simmons, JH; Szegedi, A; van der Vegte-Senden, M, 2006)	0.33
"Outpatients (n = 232) with major depressive disorder were randomly assigned to 8 weeks of treatment with either "standard" (n = 119; mean dose = 148 mg/d) or "higher" (n = 113; mean dose = 309 mg/d) dosage therapies."	( Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. Khan, A; Shelton, RC; Thase, ME, 2006)	0.33
" The dosing strategies did not, however, differ significantly in change in HAM-D21 total score or HAM-D21 response or remission rates."	( Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. Khan, A; Shelton, RC; Thase, ME, 2006)	0.33
" Although these data provide further evidence of a dose-response relationship for venlafaxine therapy results suggest that slower titration to higher doses of venlafaxine ER may improve tolerability without greatly diminishing the probability of success."	( Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. Khan, A; Shelton, RC; Thase, ME, 2006)	0.33
" Pregabalin in both dosage treatment groups (400 mg/day, p < ."	( Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Kasper, S; Montgomery, SA; Pande, AC; Tobias, K; Zornberg, GL, 2006)	0.33
" The hypomanic symptoms subsided gradually as the dosage was reduced and the patient thereafter remained in a euthymic state while on venlafaxine at a dose of 18."	( [Unipolar depression suddenly switches to hypomania in a patient who has just started taking venlafaxine]. Krol, DG; Nolen, WA, 2006)	0.33
" Participants 6 to 17 years of age who met DSM-IV criteria for generalized anxiety disorder received a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks."	( Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Kunz, NR; Riddle, MA; Rynn, MA; Yeung, PP, 2007)	0.34
"Data were combined from two similarly designed, multicenter, randomized, double-blind, parallel group studies in which patients with major depressive disorder were randomized to either duloxetine 60 mg/day or venlafaxine extended release (XR) 150 mg/day (75 mg/day for the first 2 weeks) for a 6-week fixed dosing period followed by an additional 6 weeks of treatment in which the dose could be increased up to 120 mg/day for duloxetine and 225 mg/day for venlafaxine."	( A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ, 2008)	0.35
"047) experienced sustained elevations of systolic blood pressure during the fixed dosing period."	( A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ, 2008)	0.35
" Venlafaxine extended release was administered for 24 weeks at a dosage of 75-225 mg/day."	( [Gender differences in clinical profile, response and remission of depressive patients treated with venlafaxine extended release]. Baca, E; García-Calvo, C; Prieto, R; Roca, M, )	0.13
" Following baseline evaluations, the patients were assigned to receive venlafaxine 75-225 mg/day with the mean dosage 141."	( Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Chen, YC; Lu, RB; Wu, YS, 2007)	0.34
"To determine whether the presence or absence of a fully functioning cytochrome P450 2D6 allele was associated with the dosage of the antidepressant drug venlafaxine in patients who had either adverse effects or absence of a therapeutic response to treatment with the immediate release or extended release form of venlafaxine."	( Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Black, JL; McAlpine, DE; Mrazek, DA; O'Kane, DJ, 2007)	0.34
" Their dosage was examined along with their 2D6 genotype to determine whether the presence or absence of a fully functioning 2D6 allele was associated with their venlafaxine dosage."	( Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Black, JL; McAlpine, DE; Mrazek, DA; O'Kane, DJ, 2007)	0.34
"7) sessions and venlafaxine therapy with a median daily dosage of 225 mg (IQR 150-225 mg) for a median of 4 (IQR 4-5) weeks."	( Depressed patients perception of the efficacy of electroconvulsive therapy and venlafaxine therapy. Bares, M; Cerná, L; Kopecek, M; Raszka, M; Seifertová, D; Sulak, J, 2007)	0.34
" The case study of a young female patient with a history of Major Depressive Disorder who initiated treatment with venlafaxine 75 mg/day and developed hypotension when the dosage was titrated up to 225 mg/day is described."	( Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms. Alexandrino-Silva, C; de Andrade, AG; de Toledo Ferraz Alves, TC; Nadalini Mauá, FH, 2008)	0.35
" Four weeks later, because of the persistence of psychiatric disturbance, the venlafaxine dosage was increased to 150 mg/day."	( Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Cotroneo, A; Davoli, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Seminara, G, 2008)	0.35
"Further randomized dose-finding studies are needed to learn more about the appropriate dosage in treating depression and comorbid pain with venlafaxine."	( Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: an observational study in primary care. Begré, S; Gerber, M; Traber, M; von Känel, R, 2008)	0.35
" Participants were adult outpatients who, following 8 weeks of monotherapy with an adequate dosing regimen of an SSRI other than citalopram and had not responded, met the diagnostic criteria for depression as described in the Diagnostic and statistical manual of mental disorders, fourth edition, and had a score > or =20 on the 21-item Hamilton Rating Scale for Depression (HAM-D21)."	( Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Jiang, Q; Lenox-Smith, AJ, 2008)	0.35
" They were treated during 8 weeks with velaxin in dosage 225-375 mg per day."	( [Velaxin (venlafaxine) in the treatment of anxious depression]. Il'ina, NA, 2008)	0.35
" At the end of the fourth week of treatment, a dosage increase to bupropion XR 300 mg/day or venlafaxine XR 150 mg/day was allowed if, in the opinion of the investigator, response was inadequate."	( Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Chrzanowski, W; Gee, M; Hewett, K; Krishen, A; Leary, MO; Milanova, V; Millen, L; Modell, J; Savela, A; Schmitz, M, 2009)	0.35
" Over time, he increased the dosage to 50 tablets daily (3750 mg)."	( Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. Lugoboni, F; Quaglio, G; Schifano, F, 2008)	0.35
" In conclusion, multiple dosing with venlafaxine did not influence cognitive functions in healthy humans."	( The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Kirch, W; Mueck-Weymann, M; Oertel, R; Pittrow, D; Siepmann, M; Siepmann, T, 2008)	0.35
" No evidence of greater efficacy was observed with doses >50 mg/day; a strong dose-response effect on tolerability was observed."	( An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. Germain, JM; Guico-Pabia, C; Jiang, Q; Kornstein, SG; Ninan, PT; Thase, ME, 2009)	0.35
" Greater clinical severity and low initial dosing may increase the risk of switching antidepressants."	( Antidepressant switching among adherent patients treated for depression. Hassan, M; Marcus, SC; Olfson, M, 2009)	0.35
"An open comparative study of efficacy and tolerability of velaxin (venlafaxine with prolonged action), which has been prescribed in a single dosage of 75 mg daily during 8 weeks, included 47 patients with subacute and chronic spondylogenic dorsopathy (SD)."	( [Results of a study of velaxin (venlafaxine) efficacy in patients with subacute and chronic spondylogenic dorsalgia]. Batysheva, TT; Boĭko, AN; Guseva, ME; Kamchatnov, PR; Kostenko, EV; Nesterova, OS; Otcheskaia, OV; Zaĭtsev, KA; Zhuravleva, EIu, 2009)	0.35
" Since venlafaxine is unavailable here, we supplemented her regular venlafaxine dosage of 37."	( Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. Kodaka, F; Koga, M; Miyata, H; Nakayama, K, 2009)	0.35
" Regardless of the treatment received, the following dosing schedule was applied: during the initial 4-week up-titration phase, the dosage was progressively increased from 25 mg/day (qd administration) to 150 mg/day (bid administration)."	( [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Gourion, D; Montagne, A; Olié, JP; Poirier, MF; Rostin, M, 2009)	0.35
"It is important that variations in drug metabolism during pregnancy be considered as these changes may necessitate a dosage adjustment to ensure that therapeutic failure does not occur during pregnancy."	( Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D, 2010)	0.36
", make a patient an outlier on the usual dose-response curve)."	( Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. Preskorn, SH, 2010)	0.36
" The calibration graph in case of dosage forms and in spiked plasma was found to be rectilinear in the concentrations of 15-600 ng/ml and 20-650 ng/ml respectively."	( Sensitive spectrofluorimetric method of analysis for venlafaxine in spiked rat plasma and formulations. Hoda, Q; Shahnawaz, S; Siddiqui, Z, 2010)	0.36
"This column continues the discussion of outliers on the dose-response curve begun in earlier columns."	( Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry. Preskorn, SH, 2010)	0.36
"we related medication choice and dosage range to outcomes of treatment as reflected by discharge rates and suicidality."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
" Regarding Dose Ranges, we note that wheras many patients had their dosage titrated upwards from the starting dose, most did not have the dosage titrated to the highest dose of the relevant medication."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
" Furthermore, a decision tree is proposed to evaluate if a racemate or an enantiomer drug and active metabolite bioanalysis should be executed for BA/BE regulatory submission using respective achiral or chiral assays when the drug moiety is a racemate or an enantiomer, formulated in modified-release dosage forms."	( Bioequivalence of venlafaxine modified-release capsule revisited with an innovative approach using experimental and predictive models. Goswami, D; Gurule, S; Khuroo, AH; Kumar, A; Monif, T, 2011)	0.37
" Due to the absence of the effect of the previous treatment, they were treated with venlafaxine in dosage 75-150 mg/day during 35 weeks."	( [Treatment-resistant depressions in borderline psychiatry]. Iastrebov, DV, 2011)	0.37
" After different dosage of venlafaxine treatment, the BDNF expression and cognition increased markedly."	( [Effect of venlafaxine on cognitive function and hippocampal brain-derived neurotrophic factor expression in rats with post-stroke depression]. Dai, MH; Han, Y; Li, DQ, 2011)	0.37
" Starting on day 2, venlafaxine XR was dosed at 37."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" It is concluded that sex, age and smoking should be considered for optimal dosing of patients with VEN."	( The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Deckert, J; Greiner, C; Haen, E; Hiemke, C; Jabs, B; Pfuhlmann, B; Unterecker, S, 2012)	0.38
"Patients with major depression were randomized to either active or placebo pindolol 20 mg retard daily dosage and concomitantly treated with venlafaxine for 19 days."	( A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression. Bech, P; Lunde, M; Martiny, K; Plenge, P, 2012)	0.38
" Subjects were followed for 12 weeks (6-week dosage adjustment, 6-week maintenance)."	( A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Black, KJ; Brodsky, M; Christine, CW; Como, PG; Elmer, L; Factor, SA; Fernandez, HH; Horn, S; Hyson, HC; Jiang, W; Juncos, J; Kurlan, R; Lyness, JM; Manning, C; Marsh, L; McDermott, MP; McDonald, W; Panisset, M; Pearson, N; Pfeiffer, R; Press, D; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J, 2012)	0.38
" Study treatments were dosed incrementally over a three week period, to reach daily doses of 150 mg venlafaxine and 200mg pregabalin by the CO(2) challenge test day."	( Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. Bailey, JE; Craig, K; Dawson, GR; Diaper, A; Dourish, CT; Nutt, DJ; Osman-Hicks, V; Rich, AS, 2013)	0.39
" Three months before admission to the hospital, the venlafaxine dosage had been increased to 300 mg/d because of severe depression."	( Venlafaxine-induced cholestatic hepatitis: case report and review of literature. Portmann, S; Stadlmann, S; Terracciano, LM; Tschopp, S, 2012)	0.38
"During an acute ECT phase, 319 patients were randomized to treatment with moderate dosage bilateral ECT or high-dosage right unilateral ECT."	( Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. Cooper, T; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, PB; Sackeim, HA, 2013)	0.39
" Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients."	( Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013)	0.39
" The aim of this study was to evaluate the cardiovascular (CV) effects of 3 weeks of dosing with venlafaxine, pregabalin and placebo on young healthy adults."	( Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Bailey, JE; Craig, K; Dawson, GR; Diaper, A; Dourish, CT; Nutt, DJ; Rich, AS; Wilson, SJ, 2013)	0.39
" In this case report, however, two patients with bipolar disorder developed a (hypo)mania while their dosage of venlafaxine was being gradually tapered off."	( [Development of (hypo)mania during discontinuation of venlafaxine in two patients with bipolar disorder]. Stevens, AW; Tak, LM, 2013)	0.39
" As a consequence, if a combination of valproic acid with doxepin or venlafaxine is administered, cautious dosing is advisable and TDM should be performed."	( Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. Deckert, J; Hempel, S; Pfuhlmann, B; Proft, F; Reif, A; Riederer, P; Unterecker, S, 2014)	0.4
" However, the UM patient responded to a dosage higher than the usual therapeutic range and without developing side effects, suggesting an association between CYP2D6 gene duplication and the therapeutic efficacy of venlafaxine."	( An observational study of Venlafaxine and CYP2D6 in clinical practice. Bellomo, G; Dalò, V; Gramaglia, C; Meola, S; Pollarolo, P; Prosperini, P; Ressico, F; Rolla, R; Torre, E; Vidali, M; Zeppegno, P, 2014)	0.4
" Thus controlling VH release from tablet dosage form over a prolonged period is a challenge."	( Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form. Avachat, M; Kulkarni, S; Malewar, N; Pokharkar, V, 2015)	0.65
" Whether similar observations would occur after repeated administration of such compounds in an attempt to simulate dosing in humans, or be compromised by dopaminergic-mediated adverse effects warrants further investigation."	( Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. Coudoré, F; Gardier, AM; Guiard, BP; Hache, G; Munro, G; Nguyen, TH; Peters, D; Quesseveur, G, 2015)	0.42
" Patients with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice is communicated to the treating physician, or to a control group in which patients receive care as usual."	( Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Berm, EJ; Boshuisen, M; Breuning, L; Brouwers, JR; Dhondt, T; Hak, E; Jansen, PA; Kok, RM; Maring, JG; Mulder, H; Postma, M; Risselada, AJ; van Marum, R; Venema, H; Vleugel, L; Voshaar, RC; Wilffert, B, 2015)	0.42
"Whether mini-tablets (tablets, diameters ≤6mm) belong to single- or multiple-unit dosage forms is still questionable."	( Mini-tablets versus pellets as promising multiparticulate modified release delivery systems for highly soluble drugs. Abdallah, OY; Gaber, DM; Nafee, N, 2015)	0.42
" In one case, a reduction in the dosage of clonazepam was also suggested."	( Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Bertschy, G; Carminati, F; Carminati, GG; Chabert, J; Darbellay, B; Deriaz, N; Fathi, M; Ferrero, F; Gerber, F; Kosel, MM, 2016)	0.43
"Psychoactive pharmaceuticals have been found as teratogens at clinical dosage during pregnancy."	( Maternal exposure to carbamazepine at environmental concentrations can cross intestinal and placental barriers. Aho, K; Bearden, S; Finney, B; Huber, DP; Kaushik, G; Thomas, MA; Zarbalis, KS, 2016)	0.43
"The optimised formula is superior to the available once-daily trials regarding enhanced bioavailability, dosage form versatility and ease of scaling up."	( Formulation of venlafaxine for once daily administration using polymeric material hybrids. Ibrahim, HK; Salah, S, 2016)	0.43
" Therefore, in women with a uterus, it is recommended that physicians prescribe combination therapy only to treat menopausal symptoms such as vasomotor symptoms (hot flashes) and vaginal atrophy, using the smallest effective dosage for the shortest possible duration."	( Hormone Therapy and Other Treatments for Symptoms of Menopause. Crider, M; Hill, DA; Hill, SR, 2016)	0.43
"This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy."	( A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. Dauphin, M; Geibel, B; Iosifescu, DV; Mago, R; Reynolds, J; Richards, C; Sarkis, E, 2017)	0.46
"For Montgomery-Åsberg Depression Rating Scale total score change, no significant dose-responses were observed for any candidate dose-response curve (all p>0."	( A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. Dauphin, M; Geibel, B; Iosifescu, DV; Mago, R; Reynolds, J; Richards, C; Sarkis, E, 2017)	0.46
"By showing an association between drug metabolism and VLX concentrations, efficacy and tolerance, there is a hope that testing drug metabolism pathways with a phenotypical approach would help physicians in selecting and dosing antidepressants."	( Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). Bellivier, F; Besson, M; Calvas, F; Chevret, S; Courtet, P; Cracowski, JL; Daali, Y; Davani, S; Déglon, J; Desmeules, J; Desmidt, T; Doumy, O; El-Hage, W; Galtier, F; Haesebaert, F; Haffen, E; Heron, K; Holtzmann, J; Le Corvoisier, P; Leboyer, M; Llorca, PM; Lloret-Linares, C; Molière, F; Montange, D; Morange, S; Nieto, I; Richieri, RM; Vignaud, P; Yon, L; Yrondi, A, 2017)	0.46
" The development of seizure activity under therapeutic dosing of venlafaxine should be brought to the attention of the health care prescriber."	( Seizure Induced by a Therapeutic Dose of Venlafaxine ER: A Case Report. Christian, JS; Musselman, D; Ninneman, M; Ye, C; Zhang, F, 2018)	0.48
" A positive correlation was detected between body weight and daily dosage (rs=0."	( Sex and body weight are major determinants of venlafaxine pharmacokinetics. Correll, CU; Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
" Serum concentration of citalopram and daily dosage correlated positively while daily dosage and mother milk concentration did not (rho = 0."	( Antidepressants in breast milk; comparative analysis of excretion ratios. Augustin, M; Franz, C; Gründer, G; Paulzen, M; Saßmannshausen, H; Schoretsanitis, G, 2019)	0.51
" Hence, a different dosing strategy is required among smoking and nonsmoking patients."	( Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Deckert, J; Hommers, LG; Menke, A; Samanski, L; Scherf-Clavel, M; Unterecker, S, 2019)	0.51
" Venlafaxine daily dosage did not differ between responders and non-responders (217."	( Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. Correll, CU; Endres, K; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Ridders, F; Schoretsanitis, G, 2019)	0.51
" This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray."	( Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019)	0.51
"We did a systematic review and dose-response meta-analysis of double-blind, randomised controlled trials that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 years or older) with major depression, identified from the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, PsycINFO, AMED, PSYNDEX, websites of drug licensing agencies and pharmaceutical companies, and trial registries."	( Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Cipriani, A; Cowen, PJ; Egger, M; Furukawa, TA; Leucht, S; Salanti, G, 2019)	0.51
" We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons."	( Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice. Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019)	0.51
" Opioid exposure was analyzed as prescribed (yes or no) and by morphine equivalent dosing (MED)."	( Opioid Exposure Negatively Affects Antidepressant Response to Venlafaxine in Older Adults with Chronic Low Back Pain and Depression. Jung, C; Karp, JF; Peciña, M; Stahl, ST; Weiner, DK, 2020)	0.56
" Genetic variation of the CYP2D6 isoenzyme can influence the optimal dosage needed for individual patients."	( Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). Berm, EJJ; Breuning, L; Brouwers, JRBJ; Ditters, K; Hak, E; Jansen, PAF; Kok, RM; Maring, JG; Mulder, H; Nanninga, J; Oude Voshaar, RC; Postma, M; Risselada, AJ; Stek, M; van der Schans, J; van Marum, R; van Schaik, RHN; Vleugel, L; Wilffert, B, )	0.13
" In the intervention arm (DG-I), the specific genotype accompanied by a standardized dosing recommendation based on the patients' genotype and the prescribed drug was directly communicated to the physician of the participant."	( Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). Berm, EJJ; Breuning, L; Brouwers, JRBJ; Ditters, K; Hak, E; Jansen, PAF; Kok, RM; Maring, JG; Mulder, H; Nanninga, J; Oude Voshaar, RC; Postma, M; Risselada, AJ; Stek, M; van der Schans, J; van Marum, R; van Schaik, RHN; Vleugel, L; Wilffert, B, )	0.13
" Those with prior adequate trials were also more likely to require a higher dosage of venlafaxine to achieve remission."	( Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History. Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF, 2019)	0.51
"There was no evidence to support added value in terms of efficacy, tolerability or acceptability of flexibly titrating up the dosage over the minimum licensed dose of SSRIs or mirtazapine."	( No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Cipriani, A; Cowen, PJ; Furukawa, TA; Leucht, S; Salanti, G, 2020)	0.56
"Median daily dosage of venlafaxine was 75 mg (range 37."	( Pregnancy exposure to venlafaxine-Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. Augustin, M; Franz, C; Gründer, G; Paulzen, M; Schoretsanitis, G; Stingl, JC, 2020)	0.56
"Participants with GAD and coprescribed benzodiazepines were treated with a lower mean dosage of escitalopram and were less likely to complete the trial; there was no difference in adherence or treatment response."	( Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes. Altmann, H; Blumberger, DM; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST, 2020)	0.56
" We examined the relationship of venlafaxine dosage and ECG parameters, as well as the relationship between serum levels of venlafaxine and ECG parameters."	( The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults. Behlke, LM; Blumberger, DM; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Pham, V; Reynolds, CF; Saade, Y; Smith, TW; Stefan, C, )	0.13
" This finding is of clinical relevance when adjusting dosing of CYP2D6 substrates during comedication with BUP."	( Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Arnestad, M; Haslemo, T; Hole, K; Molden, E, )	0.13
"This study strongly suggests that TDM could represent a more appropriate tool than the oral dosage to optimise the treatment with VEN."	( Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. Conca, A; De Donatis, D; Florio, V; Giupponi, G; Mercolini, L; Porcelli, S; Serretti, A; Zernig, G, 2022)	0.72
"Preclinical pharmacokinetic (PK) studies in animal models during the formulation development phase give preliminary evidence and near clear picture of the PK behavior of drug and/or its dosage forms before clinical studies on humans and help in the tailoring of the dosage form according to the expected and requisite clinical behavior."	( Multiple-reaction monitoring (MRM) LC-MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits. Ahmad, S; Fazli, AA; Khan, NA; Khuroo, A; Kumar, V; Panigrahy, BK; Raza, SN; Wani, TU; Zarger, BA, 2022)	0.72
"18 uIU/mL during venlafaxine dosage reduction from 225 mg/day to 155 mg/day."	( Venlafaxine deprescribing and thyroid function. Jain, S; Zarowitz, BJ, 2023)	0.91
"There was a direct relationship between antidepressant dosage reduction and levothyroxine dosage requirements."	( Venlafaxine deprescribing and thyroid function. Jain, S; Zarowitz, BJ, 2023)	0.91
" Pregnancy-associated physiologic changes can alter pharmacokinetics (PK) and may impact dosing requirements during pregnancy."	( Pharmacokinetics of Antidepressants in Pregnancy. Haas, DM; Katta, S; Kus, L; Li, L; Quinney, SK; Su, I; Yue, M, 2023)	0.91
" Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone."	( Treatment-Resistant Depression (TRD): Is the Opioid System Involved? Keidan, L; Pick, CG; Schreiber, S, 2023)	0.91
"An eco-friendly dispersive liquid-liquid microextraction mediated with a reverse micelle and coupled to an HPLC-DAD was developed for the simultaneous determination of venlafaxine and agomelatine in dosage forms and human plasma."	( A reverse micelle-mediated dispersive liquid-liquid microextraction coupled to high-performance liquid chromatography for the simultaneous determination of agomelatine and venlafaxine in pharmaceuticals and human plasma. El-Deen, AK; Magdy, G; Shimizu, K, 2023)	0.91

Class	Description
hydrochloride	A salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	43.6465	3.1890	29.8841	59.4836	AID1224846
GLI family zinc finger 3	Homo sapiens (human)	Potency	6.1131	0.0007	14.5928	83.7951	AID1259392
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	54.9477	0.0008	17.5051	59.3239	AID1159527
pregnane X nuclear receptor	Homo sapiens (human)	Potency	61.1306	0.0054	28.0263	1,258.9301	AID1346982
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	48.9722	19.7391	45.9784	64.9432	AID1159509
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.1636	0.0041	9.9848	25.9290	AID504444
geminin	Homo sapiens (human)	Potency	1.0000	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	2.9466	0.0008	1.5416	20.0000	AID1164248; AID1245393; AID1285850; AID1397327; AID1409105; AID1439845; AID1463521; AID1632943
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0001	0.8645	8.7096	AID1164247; AID1245392; AID1285849; AID1397326; AID1409102; AID1439844; AID1463520; AID1632941
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	9.1250	0.0007	1.8419	46.0000	AID1164249; AID1632942
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1632941	Inhibition of [3H]-5-hydroxytryptamine reuptake in human SERT expressed in HEK293 cells by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors.
AID1210253	Total drug level in wild type Crl:CF1 mouse brain expressing Abcb1a mutant at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210217	Unbound brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a at 9 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1632942	Inhibition of [3H]-5-dopamine reuptake in human DAT expressed in HEK293 cells by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors.
AID1164247	Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1164246	Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1210215	Percentage unbound in Sprague-Dawley rat plasma at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210236	Total brain to plasma partition coefficient of the compound in mdr1a-deficient rat at 9 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1409107	Inhibition of [3H]serotonin uptake at human SERT expressed in HEK293 cells at 1 uM after 15 to 20 mins by microbeta scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake.
AID1164244	Inhibition of human SERT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1409102	Inhibition of [3H]serotonin uptake at human SERT expressed in HEK293 cells after 15 to 20 mins by microbeta scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake.
AID1285849	Inhibition of [3H]-5-HT reuptake in human SERT transfected into HEK293 cells by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities.
AID1409110	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells at 1 uM after 15 to 20 mins by microbeta scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake.
AID1439845	Inhibition of [3H]-5-norepinephrine reuptake in human NET expressed in HEK293 cells by microbeta liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors.
AID1210234	Total plasma concentration in mdr1a-deficient rat at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210201	Total drug level in mdr1a-deficient mouse brain at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210220	Total drug level in wild type Sprague-Dawley rat brain expressing Abcb1a at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210221	Total brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a at 9 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1164248	Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1463521	Inhibition of re-uptake of [3H]-NE at human NET expressed in HEK293 cells by liquid scintillation counting	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
AID1210219	Total plasma concentration in wild type Sprague-Dawley rat expressing Abcb1a at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1245392	Inhibition of human SERT expressed in HEK293 cells assessed as reduction of serotonin reuptake using [3H]-SERT after 15 mins by liquid scintillation counting	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors.
AID1210200	Total plasma concentration in mdr1a-deficient mouse at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210216	Percentage unbound in Sprague-Dawley rat brain at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210254	Total brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant at 12 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210235	Total drug level in mdr1a-deficient rat brain at 9 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210180	Unbound brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant at 12 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210173	Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient rat at 9 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1439844	Inhibition of [3H]-5-hydroxytryptamine reuptake in human SERT expressed in HEK293 cells by microbeta liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors.
AID1285850	Inhibition of [3H]-NE reuptake in human NET transfected into HEK293 cells by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities.
AID1463520	Inhibition of re-uptake of [3H]-5-HT at human SERT expressed in HEK293 cells by liquid scintillation counting	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
AID1210202	Total brain to plasma partition coefficient of the compound in mdr1a-deficient mouse at 12 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210178	Percentage unbound in Crl:NMRI(Han) mouse brain at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1245393	Inhibition of human NET expressed in HEK293 cells assessed as reduction of serotonin reuptake using [3H]-NET after 15 mins by liquid scintillation counting	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors.
AID1397326	Inhibition of human SERT expressed in HEK293 cells assessed as reduction in [3H]5-HT uptake by micro beta scintillation counting analysis	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.
AID1164250	Selectivity index, ratio of IC50 for human NET to IC50 for human SERT	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1409105	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells after 15 to 20 mins by microbeta scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake.
AID1210252	Total plasma concentration in wild type Crl:CF1 mouse expressing Abcb1a mutant at 12 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210218	Percentage unbound in Crl:NMRI(Han) mouse plasma at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1632943	Inhibition of [3H]-5-norepinephrine reuptake in human NET expressed in HEK293 cells by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors.
AID1164245	Inhibition of human NET expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1210163	Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient mouse at 12 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1164249	Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1164251	Selectivity index, ratio of IC50 for human DAT to IC50 for human SERT	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1397327	Inhibition of human NET expressed in HEK293 cells assessed as reduction in [3H]-NE uptake by micro beta scintillation counting analysis	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (0.15)	18.7374
1990's	328 (12.35)	18.2507
2000's	1048 (39.47)	29.6817
2010's	1018 (38.34)	24.3611
2020's	257 (9.68)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	686 (24.10%)	5.53%
Reviews	348 (12.23%)	6.00%
Case Studies	596 (20.94%)	4.05%
Observational	14 (0.49%)	0.25%
Other	1,202 (42.23%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (196)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression [NCT00043550]	Phase 3	156 participants (Actual)	Interventional	2001-11-30	Completed
Study of Antidepressants in Parkinson's Disease [NCT00086190]	Phase 3	115 participants (Actual)	Interventional	2005-06-30	Completed
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]		300 participants (Anticipated)	Interventional	2002-01-31	Active, not recruiting
[NCT01204086]	Phase 4	200 participants (Anticipated)	Interventional	2007-03-31	Recruiting
A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI [NCT03588572]		43 participants (Actual)	Interventional	2018-08-01	Completed
An Investigation of the Role of Inflammatory Processes in the Development and Treatment of Idiopathic Unipolar and Bipolar Depression in Patients With Moderate to Severe Depressive Symptoms. [NCT03920475]		104 participants (Actual)	Observational	2015-08-05	Completed
EEG Signal Processing as a Predictor of Antidepressant Response [NCT01369290]		150 participants (Anticipated)	Observational	2009-10-31	Recruiting
Repetitive Transcranial Magnetic Stimulation (rTMS) Compared or Associated With Venlafaxine for Depressive Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study [NCT01370304]	Phase 3	60 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]		1,000 participants (Anticipated)	Interventional	2001-11-30	Active, not recruiting
Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder [NCT02346682]	Phase 4	75 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Maintenance Therapies in Late-Life Depression: MTLD III [NCT00177671]	Phase 4	220 participants (Actual)	Interventional	2003-12-31	Completed
International Committee of Medical Journal Editors [NCT02179268]	Phase 3	203 participants (Actual)	Interventional	2012-03-31	Completed
DRUG USE INVESTIGATION OF EFFEXOR(REGISTERED) SR CAPSULES [NCT02958527]		1,408 participants (Actual)	Observational	2016-10-03	Completed
Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis [NCT02476136]		8,800 participants (Anticipated)	Observational	2015-05-31	Active, not recruiting
Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fed Conditions [NCT00834249]	Phase 1	18 participants (Actual)	Interventional	2002-12-31	Completed
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression [NCT02493868]	Phase 3	719 participants (Actual)	Interventional	2015-10-01	Completed
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/Day to 2.0 mg/Day) or Extended Release Venlafaxine XR (150 mg/Day [NCT00448058]	Phase 2	396 participants (Actual)	Interventional	2007-04-30	Completed
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities - a Randomized Controlled Parallel Assigned Study [NCT05104918]	Phase 3	500 participants (Anticipated)	Interventional	2022-02-28	Not yet recruiting
Evaluating Safety and Tolerability of Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy [NCT05884268]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-05-30	Not yet recruiting
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene [NCT02237937]	Phase 4	80 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine [NCT02263248]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2014-12-31	Completed
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes [NCT04218123]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2020-02-05	Completed
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder [NCT01114698]	Phase 2	12 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Study was terminated due to sponsor portfolio decision.)
A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder. [NCT02086929]	Phase 3	364 participants (Actual)	Interventional	2012-12-31	Completed
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression [NCT03126188]		105 participants (Actual)	Observational	2017-04-05	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT00834964]	Phase 1	30 participants (Actual)	Interventional	2002-12-31	Completed
A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features) [NCT00584974]	Phase 2	523 participants (Actual)	Interventional	2007-12-31	Completed
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer [NCT03574792]		62 participants (Actual)	Interventional	2018-05-03	Completed
A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer. [NCT06106529]	Phase 3	260 participants (Anticipated)	Interventional	2024-01-08	Not yet recruiting
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression [NCT00627887]	Phase 4	56 participants (Actual)	Interventional	2008-01-31	Completed
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder [NCT02051413]	Phase 4	67 participants (Actual)	Interventional	2014-02-18	Completed
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN) [NCT06131268]	Phase 4	30 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom [NCT04961190]	Phase 4	300 participants (Anticipated)	Interventional	2022-05-25	Recruiting
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression [NCT02422186]	Phase 3	139 participants (Actual)	Interventional	2015-08-20	Completed
Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study [NCT04806230]		81 participants (Actual)	Observational	2011-04-01	Completed
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]		100 participants (Actual)	Interventional	2009-06-30	Completed
Physiologic Monitoring of Antidepressant Medication Effects in Normal Controls Subjects I [NCT00759317]	Phase 4	37 participants (Actual)	Interventional	2001-06-30	Completed
A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain [NCT00611676]	Phase 4	18 participants (Actual)	Interventional	2004-09-30	Completed
A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder [NCT00644982]	Phase 4	163 participants (Actual)	Interventional	2002-10-31	Completed
Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial [NCT00974155]	Phase 4	889 participants (Actual)	Interventional	2009-09-30	Completed
International Study to Predict Optimised Treatment - in Depression [NCT00693849]	Phase 4	2,688 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms [NCT06049797]		1,000 participants (Anticipated)	Observational	2023-11-15	Recruiting
Prolonging Remission in Depressed Elderly (PRIDE) [NCT01028508]	Phase 4	247 participants (Actual)	Interventional	2010-01-31	Completed
Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma [NCT01011751]	Phase 3	311 participants (Actual)	Interventional	2004-04-30	Completed
Treatment of Bipolar Type II Major Depression [NCT00602537]	Phase 4	140 participants (Actual)	Interventional	2007-12-31	Completed
Acute Antidepressant Therapy in Bipolar II Major Depression [NCT00641927]	Phase 4	90 participants (Actual)	Interventional	2002-04-30	Completed
Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder [NCT00839423]	Phase 2	426 participants (Actual)	Interventional	2006-08-31	Completed
Patient Dimensions as Predictors of Response, Relapse and Recurrence Following Cognitive-Behavioral Therapy, Interpersonal Psychotherapy and Pharmacotherapy Treatment of Patients With Major Depression. [NCT00744406]	Phase 2	72 participants (Actual)	Interventional	2003-07-31	Completed
A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression [NCT00789854]	Phase 3	688 participants (Actual)	Interventional	2008-11-30	Completed
A Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active-referenced Study Evaluating the Efficacy and Safety of Three Fixed Dose Regimens of Lu AA34893 in the Treatment of Major Depressive Disorder [NCT00766870]	Phase 2	35 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Study was previously paused and is now terminated)
Combined Treatment for Generalized Anxiety Disorder (GAD) [NCT00620776]	Phase 2	69 participants (Actual)	Interventional	2006-10-31	Completed
Repetitive Transcranial Magnetic Stimulation Efficacy for Major Resistant Depression Compared or Associated With Venlafaxine : a Multicentric Study. [NCT00714090]	Phase 3	170 participants (Actual)	Interventional	2008-05-31	Completed
A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor Xr On Cardiac Repolarization In Healthy Adult Subjects [NCT02637193]	Phase 1	54 participants (Actual)	Interventional	2015-12-31	Completed
Examination of the Pharmacokinetic Properties of Two Generic Antidepressants and Their Respective Brand Preparations in Healthy Male Volunteers [NCT00676039]	Phase 1	18 participants (Actual)	Interventional	2007-11-30	Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]		1,000 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules and EFEXOR® XR Under Fed Conditions in Chinese Healthy Volunteers [NCT04229602]		28 participants (Anticipated)	Interventional	2020-01-02	Recruiting
A Study Of The Utility Of Effexor® (Venlafaxine) In Achieving Response And Maintaining Remission Among Taiwanese Patients With Depression [NCT00546494]	Phase 4	350 participants	Interventional	2004-02-29	Completed
A Randomized, Double-Blind, Placebo-Controlled, Pilot Study To Evaluate The Efficacy And Safety Of Venlafaxine Extended-Release In Depressed And Anxious Patients With Multiple, Unexplained Somatic Symptoms [NCT00546923]	Phase 4	210 participants	Interventional	2004-08-31	Completed
Adapting Marital Therapy in Older Adults With Depression [NCT00612807]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2006-07-31	Completed
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets and Wyeth Pharmaceuticals (Effexor®) 50 mg Venlafaxine Hydrochloride Tablets [NCT00871364]	Phase 1	30 participants (Actual)	Interventional	2006-04-30	Completed
Incomplete Response in Late Life Depression: Getting to Remission [NCT00892047]	Phase 4	468 participants (Actual)	Interventional	2009-08-31	Completed
A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients [NCT00926835]	Phase 4	692 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to due to patient recruitment difficulties)
A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study [NCT00592384]	Phase 4	133 participants (Actual)	Interventional	2007-07-31	Completed
Physiologic Monitoring of Antidepressant Treatment Response [NCT00792168]	Phase 4	38 participants (Actual)	Interventional	1996-11-30	Completed
EEG Biomarkers of Response in Depression [NCT00759122]	Phase 4	44 participants (Actual)	Interventional	2002-11-30	Completed
Serotonin-Norepinephrine Reuptake Inhibitors for the Prevention and Treatment of Pain, Depression, and Anxiety in Patients With Head & Neck Cancer [NCT04977271]	Phase 4	205 participants (Anticipated)	Interventional	2023-07-28	Not yet recruiting
Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass [NCT01867255]	Phase 1	10 participants (Actual)	Interventional	2013-10-31	Completed
Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision [NCT01716377]	Phase 2	20 participants (Actual)	Interventional	2012-10-31	Completed
Population Pharmacokinetic and Pharmacodynamic Modeling of Gabapentin in Neuropathic Pain - Effect of Adjuvant Pharmacotherapy [NCT00967707]	Phase 2	30 participants (Anticipated)	Interventional	2009-08-31	Completed
Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study [NCT00001483]	Phase 2	75 participants	Interventional	1995-06-30	Completed
Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury [NCT00167856]		16 participants (Actual)	Interventional	2005-06-30	Completed
An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China [NCT00878748]	Phase 4	0 participants (Actual)	Interventional	2009-04-30	Withdrawn
Double-Blind, Acute Depression Study Comparing Venlafaxine XR and Lamotrigine When Added to Mood Stabilizer in the Treatment of Bipolar Depression [NCT00188643]	Phase 4	40 participants	Interventional	2002-01-31	Completed
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]	Phase 4	95 participants (Actual)	Interventional	2003-04-30	Completed
Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Progr [NCT00401726]	Phase 4	537 participants (Actual)	Interventional	2006-06-30	Completed
Short-term Versus Long-term Treatment in Generalized Anxiety Disorder [NCT00183274]	Phase 4	268 participants (Actual)	Interventional	2004-01-31	Completed
A Controlled Trial of Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder [NCT00211809]	Phase 4	17 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to low enrollment)
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer [NCT00354432]	Phase 3	120 participants (Actual)	Interventional	2007-02-01	Terminated(stopped due to Stopped by the DSMB for lack of effect per interim stopping rule.)
A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder [NCT00238719]	Phase 3	293 participants	Interventional	1999-12-31	Completed
Clinical Study on Chemotherapy Induced Peripheral Neuropathy: Preventive Approach Using Venlafaxine [NCT05875610]	Phase 4	60 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder [NCT01977378]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression [NCT00253266]	Phase 4	126 participants (Actual)	Interventional	2008-04-30	Completed
A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery [NCT02005107]	Phase 4	12 participants (Actual)	Interventional	2013-12-31	Completed
Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine [NCT04207385]	Phase 4	160 participants (Anticipated)	Interventional	2019-12-01	Recruiting
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in He [NCT01282814]	Phase 1	24 participants (Actual)	Interventional	2003-02-28	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditio [NCT01260896]	Phase 1	24 participants (Actual)	Interventional	2002-09-30	Completed
The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs & Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China [NCT00474708]	Phase 4	1,151 participants (Actual)	Interventional	2007-04-30	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
[NCT02711215]	Phase 4	80 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
The Efficacy and Safety of Acupuncture for Prophylaxis of Vestibular Migraine [NCT04664088]		72 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers [NCT00329186]	Phase 3	14 participants (Actual)	Interventional	2006-05-31	Completed
A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia [NCT00435279]	Phase 3	678 participants (Actual)	Interventional	2007-06-30	Completed
An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150m [NCT01418612]	Phase 1	0 participants	Interventional		Completed
An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150m [NCT01418625]	Phase 1	0 participants	Interventional		Completed
Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response? [NCT00186264]		18 participants (Actual)	Interventional	2002-08-31	Completed
KAVA KAVA in Generalized Anxiety: A Double-Blind Trial [NCT00083980]	Phase 2	16 participants (Actual)	Interventional	2002-06-30	Terminated(stopped due to European reports of liver toxicity from kava meant that the study had to stop)
Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression [NCT00177528]	Phase 4	70 participants	Interventional	2000-10-31	Completed
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study [NCT00177567]	Phase 4	60 participants	Interventional	2001-07-31	Completed
Evaluation of a Biobehavioral Intervention for Hot Flashes [NCT01000623]		0 participants (Actual)	Interventional	2009-11-30	Withdrawn
Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System) [NCT00205491]	Phase 4	100 participants (Anticipated)	Interventional	2004-10-31	Completed
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder [NCT00122837]	Phase 3	560 participants	Interventional	2005-04-30	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsules in Healthy Subjects Under Fed Conditions. [NCT01282801]	Phase 1	18 participants (Actual)	Interventional	2002-09-30	Completed
A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects [NCT01235338]	Phase 1	80 participants (Actual)	Interventional	2010-10-28	Completed
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial [NCT01360866]	Phase 3	2,944 participants (Actual)	Interventional	2011-10-31	Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]		90 participants (Anticipated)	Interventional	2011-11-30	Active, not recruiting
CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia: Depression, Anxiety, and Mild Cognitive Impairment [NCT02955719]		145 participants (Actual)	Interventional	2016-03-30	Completed
[NCT02934035]		10,000 participants (Anticipated)	Observational	2016-09-30	Active, not recruiting
Rescuing OSA Patients Unable to Tolerate CPAP Using Endotype-Targeted Combination Drug Therapy: a Randomized, Double-Blind, Placebo-Controlled Trial [NCT04639193]	Phase 2	20 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder. [NCT00122850]	Phase 3	480 participants	Interventional	2004-10-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder [NCT00087737]	Phase 3	369 participants (Actual)	Interventional		Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
Serotonin Effect in Non-Ulcer Dyspepsia [NCT00115362]		300 participants (Anticipated)	Interventional	2005-07-31	Completed
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-blind, Placebo-controlled Trial [NCT00150839]	Phase 4	80 participants (Actual)	Interventional	2006-03-31	Completed
A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder [NCT00179283]	Phase 3	20 participants	Interventional	2002-04-30	Completed
Placebo-Controlled Venlafaxine Treatment for Depressed Cocaine Abusers [NCT00249483]	Phase 2	150 participants (Actual)	Interventional	1999-10-31	Completed
Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression [NCT00225485]	Phase 3	100 participants	Interventional	2003-12-31	Completed
Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression [NCT00225524]	Phase 3	150 participants (Anticipated)	Interventional	2004-09-30	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-sequence Two-period, Single Dose Sprinkled on Apple Sauce, Crossover and Relative Bioavailability Study in Healthy Adult, Human Subjects Under Fed Conditions [NCT01512459]	Phase 1	33 participants (Actual)	Interventional	2006-05-31	Completed
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression [NCT02497287]	Phase 3	802 participants (Actual)	Interventional	2015-09-30	Completed
A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05973786]	Phase 4	418 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study [NCT00667121]		85 participants (Anticipated)	Observational	2011-03-16	Active, not recruiting
A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder [NCT00038896]	Phase 3	343 participants (Actual)	Interventional	2001-04-30	Completed
Optimization of Electroconvulsive Therapy [NCT00045916]	Phase 4	340 participants (Actual)	Interventional	2001-02-28	Completed
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder [NCT00067912]	Phase 4	480 participants	Interventional	2003-04-30	Completed
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder [NCT00071695]	Phase 4	320 participants	Interventional	2003-07-31	Completed
[NCT00080158]	Phase 2/Phase 3	120 participants	Interventional	2004-03-31	Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) [NCT00018902]	Phase 2/Phase 3	334 participants (Actual)	Interventional	2001-01-31	Completed
Improving Hispanic Retention in Antidepressant Therapy [NCT00057642]		50 participants (Actual)	Interventional	2002-09-30	Completed
Phase III Comparison of Depomedroxyprogesterone Acetate (DPROV) to Venlafaxine for Managing Hot Flashes [NCT00030914]	Phase 3	227 participants (Actual)	Interventional	2002-04-30	Completed
An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients [NCT00151450]	Phase 3	390 participants	Interventional	2005-03-31	Completed
A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder [NCT00044772]	Phase 3	653 participants (Actual)	Interventional	2001-11-30	Completed
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term [NCT00046020]	Phase 4	1,096 participants (Actual)	Interventional	2000-08-31	Completed
Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. [NCT00195598]	Phase 3	70 participants (Anticipated)	Interventional	2005-01-31	Completed
Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction [NCT00084669]		119 participants (Anticipated)	Interventional	2004-05-31	Completed
Venlafaxine for Hot Flashes After Breast Cancer [NCT00198250]	Phase 2	75 participants (Actual)	Interventional	2000-05-31	Completed
Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression [NCT00225511]	Phase 3	590 participants (Anticipated)	Interventional	2004-06-30	Completed
Combining Medications to Enhance Depression Outcomes [NCT00590863]	Phase 4	665 participants (Actual)	Interventional	2008-03-31	Completed
Physiologic Monitoring of Antidepressant Medication Effects in Normal Healthy Subjects II [NCT00634283]	Phase 4	6 participants (Actual)	Interventional	2008-02-29	Completed
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea [NCT02714400]	Phase 4	20 participants (Actual)	Interventional	2016-03-31	Completed
The Use of Venlafaxine in Reducing Acute Post-Surgical Pain and Opioid Consumption in Primary Total Knee Replacement [NCT05023278]	Phase 4	100 participants (Anticipated)	Interventional	2021-05-10	Recruiting
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer [NCT05724849]	Phase 2	64 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol [NCT03274817]	Phase 1	5 participants (Actual)	Interventional	2009-06-18	Terminated(stopped due to Insufficient Enrollment)
A Open-label Long-term Extension Study To Evaluate The Safety And Efficacy Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder [NCT01485887]	Phase 3	50 participants (Actual)	Interventional	2012-01-31	Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]	Phase 4	1,080 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder [NCT01824433]	Phase 4	189 participants (Actual)	Interventional	2013-03-07	Completed
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise [NCT02407704]	Phase 4	31 participants (Actual)	Interventional	2015-03-31	Completed
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD) [NCT02977299]	Phase 4	278 participants (Actual)	Interventional	2017-05-01	Completed
Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression [NCT01658228]	Phase 4	86 participants (Actual)	Interventional	2011-09-30	Completed
Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer [NCT01533753]	Phase 2	5 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Slow accrual)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder [NCT01441440]	Phase 3	538 participants (Actual)	Interventional	2011-11-30	Completed
[NCT01443520]	Phase 4	12 participants (Actual)	Interventional	2011-10-31	Completed
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05603104]	Phase 3	1,254 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects [NCT00362271]	Phase 1	38 participants	Interventional	2006-08-31	Completed
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine [NCT02181231]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2016-06-01	Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]	Phase 3	124 participants (Actual)	Interventional	2003-09-30	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02418585]	Phase 3	236 participants (Actual)	Interventional	2015-08-07	Completed
Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine [NCT00909155]		50 participants (Actual)	Interventional	2002-07-31	Completed
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks. [NCT01557712]	Phase 3	25 participants (Actual)	Interventional	2012-03-31	Completed
A Comparative Study of the Efficacy of Venlafaxine and Naltrexone for Relapse Prevention in Patients With Opioid Use Disorder Attributed to Tramadol [NCT05569031]	Phase 4	52 participants (Actual)	Interventional	2019-01-01	Completed
The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study [NCT01569685]	Phase 4	207 participants (Actual)	Interventional	2012-04-30	Completed
Improving Outcomes in Pharmacotherapy of Social Phobia [NCT00282828]	Phase 4	397 participants (Actual)	Interventional	2006-03-31	Completed
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Exte [NCT00316160]	Phase 4	347 participants	Interventional	2004-09-30	Completed
A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy [NCT01611155]		50 participants (Actual)	Interventional	2012-02-17	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
Venlafaxine for Depression in Alzheimer's Disease [NCT01609348]		5 participants (Actual)	Interventional	2012-04-30	Completed
Pilot Randomized Feasibility Trial of Tele-Interpersonal Psychotherapy and Tele-Pharmacotherapy for Depression in Patients With Non-Metastatic Breast Cancer [NCT04973930]	Phase 3	20 participants (Anticipated)	Interventional	2022-03-01	Suspended(stopped due to U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.)
Bariatric Surgery and Pharmacokinetics of Venlafaxine: BAR-MEDS Venlafaxine [NCT03532477]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy [NCT04737967]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2021-02-15	Recruiting
Comparative Effectiveness of Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome: A Controlled Randomized Study [NCT02451475]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2013-02-28	Completed
Results From a 24 Week, Double-blind, Placebo-controlled Trial of EMDR Combined With Venlafaxine XR in the Treatment of Posttraumatic Stress Disorder [NCT02433353]	Phase 4	0 participants (Actual)	Interventional	2016-01-31	Withdrawn(stopped due to PI was transferred to another base. No one else available to serve as PI.)
Effectivity of Propranolol and Venlafaxine in Treatment of Vestibular Migraine: A Randomized Controlled Clinical Trial [NCT02350985]	Phase 4	73 participants (Actual)	Interventional	2014-01-31	Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries [NCT01571453]	Phase 3	437 participants (Actual)	Interventional	2012-05-31	Completed
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms [NCT01418209]		339 participants (Actual)	Interventional	2011-11-30	Completed
Marijuana Addiction and Depression: Venlafaxine Treatment [NCT00131456]	Phase 2	123 participants (Actual)	Interventional	2004-03-31	Completed
CBT And Venlafaxine Treatments For Anxiety In Alcoholism [NCT00248612]	Phase 2/Phase 3	162 participants (Actual)	Interventional	2003-09-30	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02417064]	Phase 3	346 participants (Actual)	Interventional	2015-08-10	Completed
Factors of Treatment Response in Major Depressive Disorder [NCT00200902]	Phase 4	88 participants (Actual)	Interventional	2005-08-31	Completed
A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression [NCT01436643]	Phase 4	54 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Due to slow enrollment the study was terminated early)
Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury [NCT00735670]		34 participants (Actual)	Interventional	2008-06-30	Completed
Optimizing Care for Older Adults With Back Pain and Depression [NCT01124188]	Phase 4	263 participants (Actual)	Interventional	2010-05-31	Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers [NCT00727064]	Phase 1	14 participants (Actual)	Interventional	2008-06-30	Completed
Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain [NCT04747314]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2021-03-31	Recruiting
A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD [NCT04539951]	Phase 2	1,600 participants (Anticipated)	Interventional	2020-09-22	Recruiting
A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depressio [NCT03434041]	Phase 3	252 participants (Actual)	Interventional	2018-05-25	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00043550 (1) [back to overview]	Hamilton Rating Scale for Depression-17 Item
NCT00074815 (1) [back to overview]	Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00086190 (17) [back to overview]	Change in Beck Depression Inventory II (BDI-II)
NCT00086190 (17) [back to overview]	Change in Brief Psychiatric Rating Scale (BPRS)
NCT00086190 (17) [back to overview]	Change in Geriatric Depression Rating Scale (GDS)
NCT00086190 (17) [back to overview]	Change in Hamilton Depression Rating Scale (HAM-D) Scores
NCT00086190 (17) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00086190 (17) [back to overview]	Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being
NCT00086190 (17) [back to overview]	Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall
NCT00086190 (17) [back to overview]	Change in Pittsburgh Sleep Quality Index (PSQI)
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Mental Component Summary
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Mental Health
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Role-Emotional
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Vitality
NCT00086190 (17) [back to overview]	Change in Snaith Clinical Anxiety Scale (CAS)
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS)
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor
NCT00131456 (1) [back to overview]	Two Consecutive Weeks of Marijuana Abstinence
NCT00177671 (4) [back to overview]	Global Cognitive Performance
NCT00177671 (4) [back to overview]	Percentage of Participants With Mild Cognitive Impairment Converting to Dementia.
NCT00177671 (4) [back to overview]	Number of Participants With Recurrence of Major Depression
NCT00177671 (4) [back to overview]	Cognitive Instrumental Activities of Daily Living (IADL)
NCT00183274 (2) [back to overview]	Hamilton Rating Scale for Anxiety
NCT00183274 (2) [back to overview]	Clinical Global Impressions, Severity of Illness
NCT00200902 (3) [back to overview]	Change in Hamilton Depression Assessment Score
NCT00200902 (3) [back to overview]	Average Change in 3 Weeks of Participant Treatment Expectations
NCT00200902 (3) [back to overview]	Response as Assessed by Participants' Change in Depression Rating
NCT00211809 (6) [back to overview]	Beck Depression Inventory II
NCT00211809 (6) [back to overview]	Yale Brown Obsessive Scale
NCT00211809 (6) [back to overview]	Body Dysmorphic Disorder Examination
NCT00211809 (6) [back to overview]	Brown Assessment of Beliefs Scale
NCT00211809 (6) [back to overview]	Body Dysmorphic Disorder Clinical Global Impressions Scale
NCT00211809 (6) [back to overview]	Beck Anxiety Inventory
NCT00248612 (9) [back to overview]	Medication Compliance Rates
NCT00248612 (9) [back to overview]	Clinical Global Impression Scale-I (CGI-I)
NCT00248612 (9) [back to overview]	Treatment Completion
NCT00248612 (9) [back to overview]	Number of Participants Abstinent
NCT00248612 (9) [back to overview]	HAM-A Scale
NCT00248612 (9) [back to overview]	Craving Desire Scale (CDS)
NCT00248612 (9) [back to overview]	HAM-D Scale
NCT00248612 (9) [back to overview]	DASS Stress Subscale Score
NCT00248612 (9) [back to overview]	Clinical Global Impression Scale-S (CGI-S)
NCT00282828 (2) [back to overview]	Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders
NCT00282828 (2) [back to overview]	Post-treatment Social Phobia Severity as Defined by Endpoint LSAS Scores
NCT00354432 (2) [back to overview]	Quality of Life
NCT00354432 (2) [back to overview]	Hot Flash Symptom Severity Score
NCT00401726 (8) [back to overview]	Patient Global Impression of Improvement (PGI-I) Score
NCT00401726 (8) [back to overview]	Number of Patients Compliant With Therapy
NCT00401726 (8) [back to overview]	Change in WHO 5-item Well Being Index Score From Baseline to 16 Weeks
NCT00401726 (8) [back to overview]	"Number of Patients Responding Very Satisfied on Satisfaction With Depression Care Scale (SDCS)"
NCT00401726 (8) [back to overview]	Number of Patients by Clinical Global Improvement - Global Improvement Score at 16 Weeks
NCT00401726 (8) [back to overview]	Change in Inventory of Depressive Symptomatology - Self-Report (IDS-SR) Score From Baseline to 16 Weeks
NCT00401726 (8) [back to overview]	Change in 17-item Hamilton Depression Scale Score From Baseline to 16 Weeks
NCT00401726 (8) [back to overview]	Change in Sheehan Disability Scale Score From Baseline to 16 Weeks
NCT00474708 (2) [back to overview]	Number of Patients Achieving Remission
NCT00474708 (2) [back to overview]	Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status)
NCT00590863 (2) [back to overview]	Quality of Life Inventory
NCT00590863 (2) [back to overview]	Quick Inventory of Depressive Symptoms
NCT00592384 (2) [back to overview]	Hamilton Depression Rating Scale-Maier Subscale
NCT00592384 (2) [back to overview]	Hamilton Depression Rating Scale-17
NCT00602537 (2) [back to overview]	Treatment-Emergent Mood Symptoms
NCT00602537 (2) [back to overview]	Depressive Relapse
NCT00612807 (2) [back to overview]	Hamilton Depression Rating Scale (HDRS)
NCT00612807 (2) [back to overview]	Dyadic Adjustment Scale (DAS)
NCT00620776 (12) [back to overview]	Hamilton Anxiety Rating Scale (HAM-A)
NCT00620776 (12) [back to overview]	Hamilton Rating Scale for Depression (HAM-D)-17-item Score
NCT00620776 (12) [back to overview]	Hospital Anxiety Depression Scale (HAD)-Anxiety Score
NCT00620776 (12) [back to overview]	Hospital Anxiety Depression Scale (HAD)-Depression Score
NCT00620776 (12) [back to overview]	Mental Component Score of the 12-item Short Form Survey (SF-12)
NCT00620776 (12) [back to overview]	Penn State Worry Questionnaire (PSWQ)
NCT00620776 (12) [back to overview]	Physical Component Score of the 12-Item Short Form Survey (SF-12)
NCT00620776 (12) [back to overview]	Quality of Life Subscale of the General Health Questionnaire (GHQ)
NCT00620776 (12) [back to overview]	Clinical Response Rate
NCT00620776 (12) [back to overview]	50 Percent or Greater Reduction in PSWQ Score
NCT00620776 (12) [back to overview]	Clinical Global Impression (CGI)-Improvement Score
NCT00620776 (12) [back to overview]	Clinical Global Impression (CGI)-Severity Score
NCT00634283 (2) [back to overview]	Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks).
NCT00634283 (2) [back to overview]	Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over 1 Week Placebo lead-in.
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Desvenlafaxine After Single Dose of DVS SR by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Venlafaxine After Single Dose of Venlafaxine Extended-release (VEN ER) by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Desvenlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Desvenlafaxine After Single Dose of Desvenlafaxine Succinate Sustained-Release (DVS SR) by Metabolizer Status
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Venlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Desvenlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00735670 (2) [back to overview]	16-Item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)
NCT00735670 (2) [back to overview]	Depression Scale of the Patient Health Questionnaire (PHQ-9)
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), All Patients
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
NCT00789854 (30) [back to overview]	Change in Pain, Measured by Visual Analog Scale (VAS)
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component
NCT00789854 (30) [back to overview]	Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4
NCT00789854 (30) [back to overview]	Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)
NCT00789854 (30) [back to overview]	Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Beck Depression Inventory (BDI)
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by STAI, Trait Anxiety Inventory
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by Visual Analog Scale (VAS)
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients
NCT00834249 (6) [back to overview]	Cmax - O-Desmethylvenlafaxine in Plasma
NCT00834249 (6) [back to overview]	Cmax - Maximum Observed Concentration - Venlafaxine in Plasma
NCT00834249 (6) [back to overview]	AUC0-t - O-desmethylvenlafaxine in Plasma
NCT00834249 (6) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma
NCT00834249 (6) [back to overview]	AUC0-inf - O-desmethylvenlafazine in Plasma
NCT00834249 (6) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma
NCT00834964 (6) [back to overview]	Cmax - O-Desmethylvenlafaxine in Plasma
NCT00834964 (6) [back to overview]	AUC0-t - O-Desmethylvenlafaxine in Plasma
NCT00834964 (6) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma
NCT00834964 (6) [back to overview]	AUC0-inf - O-Desmethylvenlafaxine in Plasma
NCT00834964 (6) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma
NCT00834964 (6) [back to overview]	Cmax - Maximum Observed Concentration - Venlafaxine in Plasma
NCT00839423 (8) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 6
NCT00839423 (8) [back to overview]	Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10)
NCT00839423 (8) [back to overview]	Change From Baseline in MADRS Total Score After 1 Week of Treatment
NCT00839423 (8) [back to overview]	Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT00839423 (8) [back to overview]	Change From Baseline in CGI-S Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in MADRS Total Score After 6 Weeks of Treatment
NCT00892047 (6) [back to overview]	Akathisia
NCT00892047 (6) [back to overview]	Emergent Suicidal Ideation in Those With no Ideation at the Start of Treatment
NCT00892047 (6) [back to overview]	Parkinsonism
NCT00892047 (6) [back to overview]	Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00892047 (6) [back to overview]	QTc Prolongation on EKG (to Greater or Equal to 480 Msec)
NCT00892047 (6) [back to overview]	Weight
NCT00909155 (2) [back to overview]	Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.
NCT00909155 (2) [back to overview]	Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales
NCT01124188 (3) [back to overview]	Changes in Short Physical Performance Battery From Ph 2 Baseline Till 14 Weeks
NCT01124188 (3) [back to overview]	Proportion Responding Initially by Treatment Arm During 14 Weeks Post Randomization
NCT01124188 (3) [back to overview]	Change in Roland Morris Disability Questionnaire (RMDQ) From P2 Baseline to 14 Weeks
NCT01235338 (18) [back to overview]	Tmax of Venlafaxine Hydrochloride
NCT01235338 (18) [back to overview]	Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate
NCT01235338 (18) [back to overview]	AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine)
NCT01235338 (18) [back to overview]	AUC of d-Amphetamine
NCT01235338 (18) [back to overview]	AUC of o-Desmethylvenlafaxine
NCT01235338 (18) [back to overview]	AUC of Venlafaxine Hydrochloride
NCT01235338 (18) [back to overview]	Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)
NCT01235338 (18) [back to overview]	Cmax of d-Amphetamine
NCT01235338 (18) [back to overview]	Cmax of o-Desmethylvenlafaxine
NCT01235338 (18) [back to overview]	Cmax of Venlafaxine Hydrochloride
NCT01235338 (18) [back to overview]	Diastolic Blood Pressure
NCT01235338 (18) [back to overview]	Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate
NCT01235338 (18) [back to overview]	Pulse Rate
NCT01235338 (18) [back to overview]	Systolic Blood Pressure
NCT01235338 (18) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate
NCT01235338 (18) [back to overview]	Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)
NCT01235338 (18) [back to overview]	Tmax of d-Amphetamine
NCT01235338 (18) [back to overview]	Tmax of o-Desmethylvenlafaxine
NCT01260896 (6) [back to overview]	AUC0-inf of Venlafaxine.
NCT01260896 (6) [back to overview]	AUC0-inf of O-Desmethylvenlafaxine.
NCT01260896 (6) [back to overview]	Cmax of O-Desmethylvenlafaxine.
NCT01260896 (6) [back to overview]	AUC0-t of O-Desmethylvenlafaxine.
NCT01260896 (6) [back to overview]	AUC0-t of Venlafaxine.
NCT01260896 (6) [back to overview]	Cmax of Venlafaxine.
NCT01282801 (6) [back to overview]	Cmax of O-Desmethylvenlafaxine.
NCT01282801 (6) [back to overview]	Cmax of Venlafaxine.
NCT01282801 (6) [back to overview]	AUC0-inf of Venlafaxine.
NCT01282801 (6) [back to overview]	AUC0-inf of O-Desmethylvenlafaxine.
NCT01282801 (6) [back to overview]	AUC0-t of O-Desmethylvenlafaxine.
NCT01282801 (6) [back to overview]	AUC0-t of Venlafaxine.
NCT01282814 (3) [back to overview]	AUC0-inf of Venlafaxine.
NCT01282814 (3) [back to overview]	AUC0-t of Venlafaxine.
NCT01282814 (3) [back to overview]	Cmax of Venlafaxine.
NCT01360866 (5) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score
NCT01360866 (5) [back to overview]	Adverse Events (AEs) - All Participants
NCT01360866 (5) [back to overview]	Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score
NCT01360866 (5) [back to overview]	Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score
NCT01360866 (5) [back to overview]	Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
NCT01418209 (8) [back to overview]	Frequency of Hot Flashes (Daily Vasomotor Symptom [VMS] Frequency) -- Week 8
NCT01418209 (8) [back to overview]	Frequency of Hot Flashes (Vasomotor Symptom [VMS] Frequency) -- Week 4
NCT01418209 (8) [back to overview]	Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 4
NCT01418209 (8) [back to overview]	Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 8
NCT01418209 (8) [back to overview]	Severity of Hot Flashes -- Week 4
NCT01418209 (8) [back to overview]	Severity of Hot Flashes -- Week 8
NCT01418209 (8) [back to overview]	Bothersomeness of Hot Flashes -- Week 8
NCT01418209 (8) [back to overview]	Bothersomeness of Hot Flashes -- Week 4
NCT01436643 (1) [back to overview]	Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death
NCT01441440 (6) [back to overview]	Changes From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or Early Termination
NCT01441440 (6) [back to overview]	Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 8 or Early Termination
NCT01441440 (6) [back to overview]	Changes From Baseline in 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score at Week 8 or Early Termination
NCT01441440 (6) [back to overview]	Changes From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) Total Score at Week 8 or Early Termination
NCT01441440 (6) [back to overview]	Changes From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 8 or Early Termination
NCT01441440 (6) [back to overview]	Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination
NCT01485887 (9) [back to overview]	Number of Participants With no at Baseline and Yes at Any Post Baseline for Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
NCT01485887 (9) [back to overview]	Mean Clinical Global Impression - Improvement (CGI-I) Score at Each Post Baseline Time Point
NCT01485887 (9) [back to overview]	Change From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) at Each Post Baseline Time Point
NCT01485887 (9) [back to overview]	Change From Baseline in 17-item Hamilton Rating Scale for Depression (HAM-D17) at Each Post Baseline Time Point
NCT01485887 (9) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) at Each Post Baseline Time Point
NCT01485887 (9) [back to overview]	Number of Participants With Clinical Significant Electrocardiogram (ECG) Changes
NCT01485887 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01485887 (9) [back to overview]	Number of Participants With Clinical Significant Laboratory Tests Changes
NCT01485887 (9) [back to overview]	Number of Participants With Clinical Significant Vital Changes
NCT01571453 (6) [back to overview]	Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)
NCT01571453 (6) [back to overview]	MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)
NCT01571453 (6) [back to overview]	Change in HAM-A Total Score From Baseline to Week 8
NCT01571453 (6) [back to overview]	Change in CGI-S Score From Baseline to Week 8
NCT01571453 (6) [back to overview]	CGI-I Score at Week 8
NCT01571453 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8
NCT01611155 (2) [back to overview]	Cycle 1 Acute Neuropathy as Measured by EORTC QLQ CIPN20 Motor Subscale (Items 37, 38, 41-45 and 49), and Autonomic Scale (Items 46, 47, 50)
NCT01611155 (2) [back to overview]	Cycle 1 Sensory Neuropathy Score (Items 31-36, 39, 40 and 48) of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20
NCT01658228 (3) [back to overview]	Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
NCT01658228 (3) [back to overview]	Selective Reminding Test (SRT) Delayed Recall
NCT01658228 (3) [back to overview]	Selective Reminding Test (SRT) Total Recall
NCT01916824 (1) [back to overview]	Money Earned
NCT02181231 (6) [back to overview]	Brief Symptom Inventory-Anxiety Subscale (BSI)
NCT02181231 (6) [back to overview]	Suicide Ideation Scale (SIS)
NCT02181231 (6) [back to overview]	Antidepressant Side Effect Checklist (ASEC)
NCT02181231 (6) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS)
NCT02181231 (6) [back to overview]	Numeric Scale of Pain (NRS-P)
NCT02181231 (6) [back to overview]	Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)
NCT02407704 (7) [back to overview]	Physical Activity (SenseWear Physical Activity-monitoring Armband)
NCT02407704 (7) [back to overview]	Neurocognitive Function (Neuropsychological Battery)
NCT02407704 (7) [back to overview]	Functional Magnetic Resonance Imaging (fMRI)
NCT02407704 (7) [back to overview]	Cardiovascular Fitness (Submaximal VO2)
NCT02407704 (7) [back to overview]	Number of Participants Experiencing Remission
NCT02407704 (7) [back to overview]	Inflammatory Biomarkers
NCT02407704 (7) [back to overview]	Genetic Biomarkers
NCT02417064 (16) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis
NCT02417064 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score
NCT02417064 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8
NCT02418585 (16) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Health Status Index
NCT02422186 (8) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Sum Score
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): EQ-VAS
NCT02422186 (8) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis on Ranks
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Sum Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in PHQ-9 Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items (GAD-7) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level Sum Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02714400 (5) [back to overview]	Arousal Threshold
NCT02714400 (5) [back to overview]	Sleep Efficiency
NCT02714400 (5) [back to overview]	Loop Gain
NCT02714400 (5) [back to overview]	Nadir Oxygen Level During Sleep
NCT02714400 (5) [back to overview]	The Apnea Hypopnea Index
NCT02958527 (5) [back to overview]	Number of Participants With Adverse Drug Reactions
NCT02958527 (5) [back to overview]	Clinical Global Impressions-Severity
NCT02958527 (5) [back to overview]	Changes in the Clinical Global Impressions-Improvement
NCT02958527 (5) [back to overview]	Change From Baseline in the Montgomery - Asberg Depression Rating Scale (MADRS) Total Scores at Pre-specified Evaluation Points
NCT02958527 (5) [back to overview]	Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) Total Scores at Pre-specified Evaluation Points
NCT03434041 (12) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)
NCT03434041 (12) [back to overview]	Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index
NCT03434041 (12) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Percentage of Participants With Onset of Clinical Response
NCT03434041 (12) [back to overview]	Percentage of Participants With Sustained Remission
NCT03434041 (12) [back to overview]	Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)
NCT03588572 (6) [back to overview]	A Change of Outcome Measure:the Chinese Version of Western Aphasia Battery(WAB)
NCT03588572 (6) [back to overview]	Follow-up Measurement: Hamilton Anxiety Rating Scale (HAMA)
NCT03588572 (6) [back to overview]	Follow-up Measurement: Hamilton Depression Rating Scale (HAMD)
NCT03588572 (6) [back to overview]	A Change of Outcome Measure:Spontaneous Language Frequency Test(SLFT)
NCT03588572 (6) [back to overview]	Follow-up Measurement: Mini-Mental State Examination (MMSE)
NCT03588572 (6) [back to overview]	A Change of Outcome Measure:Picture Naming Test(PNT)

Hamilton Rating Scale for Depression-17 Item

Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). We used the 17-item version of the 27-item HRSD, a measure of depression severity. The Structured Interview Guide was used to conduct the interviews (SIGH-D; Williams, 1988). The reliability and validity of the HRSD are well documented (Rabkin & Klein, 1987). Interjudge reliability as assessed by interclass correlations was .92 in our sample. Total 17-item scores could range from 17-48 with higher scores indicating greater distress. (NCT00043550)
Timeframe: symptoms assessed during past 7 days, measure taken at baseline, week 8 and week 16

Intervention	units on a scale (Mean)
	Initial HRSD-17	Mid-treatment HRSD-17	LOCF HRSD-17
1 Sertraline	19.0	13.9	14.2
2 Supportive-expressive Psychotherapy	19.9	12.5	14.5
3 Pill Placebo	19.4	12.7	14.3

Intervention	Change in PDQ-39 Emotional score (Mean)
Paroxetine	-21.4
Venlafaxine Extended Release	-20.7
Placebo	-10.9

Intervention	Z-score (Mean)
	Baseline (N=67;N=63)	Year 1 (N=45; N=57)	Year 2 N=42; N=49)
Donepezil	-0.47	-0.23	-0.31
Placebo	-0.47	-0.65	-0.56

Intervention	Percentage of participants (Number)
	Baseline (N=33; N=34)	Year 1 (N=23; N=25)	Year 2 (N=11; N=17)
Donepezil	54.10	62.16	36.67
Placebo	61.82	54.35	47.22

Intervention	HAM-A Rating Score (Mean)
Open-Label: Venlafaxine XR	4.17
Double-Blind Venlafaxine XR	6.29
Double-Blind Placebo	11.35
Double-Blind Relapse Drug After Drug	5.80
Double-Blind Relapse Placebo After Drug	8.42
Double-Blind Placebo After Placebo	6.19

Intervention	Severity Score (Mean)
Phase 1: Open-Label Venlafaxine XR	1.37
Phase 2: Double-Blind Venlafaxine XR	1.73
Phase 2: Double-Blind Placebo	2.64
Phase 3: Double-Blind Drug After Drug	1.86
Phase 3: Placebo After Drug	2.25
Placebo After Placebo	1.95

Intervention	HAMD score (Mean)
	Percent Change in HAM-D	Change in HAM-D
Interpersonal Clinical Interaction (ICI)	-0.05	-1.37
Medication (MED)	-0.46	-10.05
Placebo (PBO)	-0.36	-7.59

Intervention	units on a scale (Mean)
Medication (MED)	3.55
Placebo (PBO)	3.94
Interpersonal Clinical Interaction (ICI)	3.17

Intervention	Participants (Count of Participants)
	Responders	Remitters
Interpersonal Clinical Interaction (ICI)	1	0
MEDICATIONS	17	9
Placebo (PBO)	11	9

Intervention	units on a scale (Mean)
	Psychiatrist's Ratings for Total	Psychiatrist's Ratings for Obsessions	Psychiatrist's Ratings for Compulsions	Psychologist's Ratings for Total	Psychologist's Ratings for Obsessions	Psychologist's Ratings for Compulsions
Baseline	34.64	14.73	14.82	35.91	14.45	16.09
Endpoint	26.55	11.45	11.55	28.27	12.09	12.18

Intervention	units on a scale (Mean)
	Psychiatrist's Ratings	Psychologist's Ratings
Baseline	15.82	15.91
Endpoint	16.91	14.82

Intervention	units on a scale (Mean)
	Psychiatrist's Ratings	Psychologist's Ratings
Body Dysmorphic Disorder	2.73	3.00

Intervention	percentage of participants (Number)
Venlafaxine & CBT	96.89
Placebo & CBT	97.06
Venlafaxine & PMR	88.70
Placebo & PMR	95.39

Intervention	units on a scale (Mean)
	Session 1 CGI-I	Session 8 CGI-I	Session 11 CGI-I
Placebo & CBT	3.81	3.13	2.61
Placebo & PMR	4.05	3.53	2.92
Venlafaxine & CBT	3.65	3.61	3.13
Venlafaxine & PMR	3.86	3.50	3.00

Intervention	units on a scale (Least Squares Mean)
	Session 1 HAM-A	Session 8 HAM-A
Placebo & CBT	14.2	9.1
Placebo & PMR	12.9	9.1
Venlafaxine & CBT	13.5	9.8
Venlafaxine & PMR	16.5	7.9

Intervention	units on a scale (Mean)
	Session 1 CDS	Session 8 CDS	Session 11 CDS
Placebo & CBT	8.14	7.41	6.11
Placebo & PMR	7.55	5.56	4.25
Venlafaxine & CBT	8.63	6.44	4.38
Venlafaxine & PMR	8.21	4.45	5.10

Intervention	units on a scale (Least Squares Mean)
	Session 1 HAM-D	Session 8 HAM-D
Placebo & CBT	11.7	8.5
Placebo & PMR	13.6	10
Venlafaxine & CBT	12.0	8.8
Venlafaxine & PMR	13.0	5.9

Intervention	units on a scale (Least Squares Mean)
	Session 1 DASS stress subscale	Session 11 DASS stress subscale
Placebo & CBT	19.2	9.6
Placebo & PMR	16.6	11.2
Venlafaxine & CBT	16.7	8.1
Venlafaxine & PMR	21.5	4.1

Intervention	units on a scale (Mean)
	Session 1 CGI-S	Session 8 CGI-S	Session 11 CGI-S
Placebo & CBT	3.76	2.88	2.53
Placebo & PMR	4.18	3.40	2.85
Venlafaxine & CBT	4.00	3.28	3.00
Venlafaxine & PMR	3.93	3.25	2.60

Intervention	participants (Number)
Sertraline and Clonazepam	17
Venlafaxine	11
Sertraline and Placebo	10

Intervention	units on a scale (Least Squares Mean)
Arm I - Placebo	115.6
Arm II - Soy	121.5
Arm III - Venlafaxine	114.3
Arm IV - Soy + Venlafaxine	117.7

venlafaxine hydrochloride

Description

Cross-References

Synonyms (121)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Inhibition Measurements

Biological Processes (55)

Molecular Functions (28)

Ceullar Components (19)

Bioassays (58)

Research

Studies (2,655)

Market Indicators

Research Demand Index: 62.67

Study Types

Clinical Trials (196)

Trial Overview

Trial Outcomes

Hamilton Rating Scale for Depression-17 Item

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Change in Beck Depression Inventory II (BDI-II)

Change in Brief Psychiatric Rating Scale (BPRS)

Change in Geriatric Depression Rating Scale (GDS)

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Change in Pittsburgh Sleep Quality Index (PSQI)

Change in Short Form 36 Health Survey - Mental Component Summary

Change in Short Form 36 Health Survey - Mental Health

Change in Short Form 36 Health Survey - Role-Emotional

Change in Short Form 36 Health Survey - Vitality

Change in Snaith Clinical Anxiety Scale (CAS)

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Two Consecutive Weeks of Marijuana Abstinence

Global Cognitive Performance

Percentage of Participants With Mild Cognitive Impairment Converting to Dementia.

Number of Participants With Recurrence of Major Depression

Cognitive Instrumental Activities of Daily Living (IADL)

Hamilton Rating Scale for Anxiety

Clinical Global Impressions, Severity of Illness

Change in Hamilton Depression Assessment Score

Average Change in 3 Weeks of Participant Treatment Expectations

Response as Assessed by Participants' Change in Depression Rating

Beck Depression Inventory II

Yale Brown Obsessive Scale

Body Dysmorphic Disorder Examination

Brown Assessment of Beliefs Scale

Body Dysmorphic Disorder Clinical Global Impressions Scale

Beck Anxiety Inventory

Medication Compliance Rates

Clinical Global Impression Scale-I (CGI-I)

Treatment Completion

Number of Participants Abstinent

HAM-A Scale

Craving Desire Scale (CDS)

HAM-D Scale

DASS Stress Subscale Score

Clinical Global Impression Scale-S (CGI-S)

Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders

Post-treatment Social Phobia Severity as Defined by Endpoint LSAS Scores

Quality of Life

Hot Flash Symptom Severity Score

Patient Global Impression of Improvement (PGI-I) Score

Number of Patients Compliant With Therapy

Change in WHO 5-item Well Being Index Score From Baseline to 16 Weeks

"Number of Patients Responding Very Satisfied on Satisfaction With Depression Care Scale (SDCS)"

Number of Patients by Clinical Global Improvement - Global Improvement Score at 16 Weeks

Intervention	percent of baseline score (Least Squares Mean)
Arm I - Placebo	52.3
Arm II - Soy	77.2
Arm III - Venlafaxine	68.9
Arm IV - Soy + Venlafaxine	73.8

Intervention	units on scale (Mean)
Venlafaxine Extended Release (ER)	2.33
Venlafaxine Extended Release (ER) Plus Dialogues	2.51

Intervention	units on scale (Mean)
Venlafaxine Extended Release (ER)	6.86
Venlafaxine Extended Release (ER) Plus Dialogues	6.97

Intervention	patients (Number)
	CGI - 1 (very much improved)	CGI - 2 (much improved)	CGI - 3 (improved)	CGI - 4 (no change)	CGI - 5 (worse)	CGI - 6 (much worse)	CGI - 7 (very much worse)
Venlafaxine Extended Release (ER)	82	84	50	24	11	2	0
Venlafaxine Extended Release (ER) Plus Dialogues	81	75	49	21	8	5	0

Intervention	units on scale (Mean)
Venlafaxine Extended Release (ER)	-17.75
Venlafaxine Extended Release (ER) Plus Dialogues	-17.50

Intervention	units on scale (Mean)
Venlafaxine Extended Release (ER)	-10.87
Venlafaxine Extended Release (ER) Plus Dialogues	-11.03

Intervention	units on scale (Mean)
Venlafaxine Extended Release (ER)	-7.99
Venlafaxine Extended Release (ER) Plus Dialogues	-6.99

Intervention	participants (Number)
Venlafaxine XR	554
SSRI or Conventional Antidepressant Group	207

Intervention	participants (Number)
	Co-morbid anxiety disorder	No anxiety disorder
SSRI or Conventional Antidepressant Group	23	184
Venlafaxine XR	60	494

Intervention	units on a scale (Mean)
Escitalopram + Bupropion SR	0.6
Venlafaxine XR + Mirtazapine	0.4
Escitalopram + Placebo	0.4